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ABSTRACT 
The etiology of Alzheimer’ s disease (AD) is still unresolved, even if it is becoming 
clearer that inflammation, a process associated to the onset of several 
neurodegenerative disorders, plays a central role in this disease. Inflammation is a 
key component of innate immune system. Innate immunity is a very highly 
conserved system that protects the host from infections in a non-specific manner. 
Even if this system provides a powerful response to a range of insults it must be 
tightly regulated: deregulation and chronic activation can have detrimental effects 
on the host. Chronic inflammation has been involved not only in peripheral 
diseases but also in neurodegenerative diseases of the central nervous system, 
like Alzheimer’s disease.  
Our working hypothesis is that inflammation plays a negative role in this pathology 
and that the mechanisms regulating the inflammatory responses are functional 
compromised in AD patients compared to Mild cognitive impairment (MCI) and to 
healthy controls (HC). 
One of the main way in which immunologic tolerance is modulated is through T 
regulatory cells (Treg). Our results indicate that the development of AD is 
associated with a reduction of circulating T reg naïve cells, the subpopulation of 
Treg cells endowed with the strongest suppressive ability. These quantitative 
changes are associated with qualitative changes, summarized as an increase of 
A-specific proliferation and a reduced ability of Treg to suppress such 
proliferation. 
The analysis of the PD-1/PD-L1 pathway, which modulates the balance between 
inflammation and tolerance by inducing IL-10 production and apoptosis of antigen-
specific cells, shows a decrease of PD-1 expressing CD4
+
 T cells in AD and MCI 
compared to HC as well as a decrease of PD-L1- expressing and IL-10-producing 
CD14
+
 cells. The impairment of the PD-1/PD-L1 pathway in AD patients results in 
reduced IL-10 production and diminished apoptosis of A-specific CD4
+
 T 
lymphocytes. The central role performed by PD-1/PD-L1 pathway in inducing the 
apoptosis of A-specific T cells is confirmed by the observation that apoptosis is 
inhibited pre-incubating lymphocytes with a PD-L1-specific blocking antibody. 
The analysis of lymphocytes subpopulations in AD and MCI compared to controls 
highlight that in AD patients not only an alteration of immunological tolerance is 
present but also a shift in the differentiation of T lymphocytes towards an 
inflammatory phenotype Th-9 and Th-17. 
Our results showed indeed that cytokines (IL-21, IL-23, IL-6) and transcription 
factor (RORc/) involved in the differentiation of Th-17, as well as cytokines (IL-21, 
IL-22) produced by these cells are all augmented in AD compared to MCI and HC. 
Notably, IL-9, the effector cytokine produced by Th-9 cells, was significantly 
increased as well in AD patients, indicating that, beside Th-17, A- specific Th-9 
lymphocytes are upregulated in AD. In conclusion the impairment of the immune 
response, with a profound skewing favoring inflammatory and effector responses, 
seem to play a pivotal role in this pathology. 
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SOMMARIO 
La patogenesi dell' Alzheimer (AD) non è nota, tuttavia è sempre più chiaro che l’ 
infiammazione, processo associato all’insorgenza di numerose malattie 
neurodegenerative del sistema nervoso centrale, svolga un ruolo in tale patologia. 
L’infiammazione è una componente chiave della risposta immunitaria innata. 
L’immunità innata è un sistema altamente conservato che protegge l’ospite dalle 
infezioni in maniera aspecifica. Sebbene questo sistema rappresenti una risposta 
efficace e potente agli stimoli acuti è necessario che sia finemente regolato: una 
deregolazione o un’attivazione cronica possono infatti avere effetti dannosi per 
l’ospite. L’infiammazione cronica è stata implicata non solo in malattie periferiche 
ma anche in malattie neurodegenerative del sistema nervoso centrale come 
l’Alzheimer.  
L’ipotesi di questo lavoro è stata che l’infiammazione rappresenti un fattore 
negativo per la malattia di Alzheimer e che i meccanismi che concorrono a regolare 
la risposta infiammatoria siano quantitativamente e funzionalmente compromessi 
negli AD rispetto agli MCI e HC. 
Uno dei meccanismi di regolazione della tolleranza immunologica è rappresentato 
dai linfociti Treg. I risultati presentati indicano che lo sviluppo della patologia di AD 
è associato ad una diminuzione del numero di Treg circolanti e in particolare della 
percentuale di Treg naive. Quest’alterazione quantitativa è associata ad 
un’alterazione qualitativa quale un’aumentata proliferazione amiloide- specifica e 
ad una ridotta capacità dei Treg di sopprimere tale proliferazione.  
L’analisi del pathway PD1-PDL1, in grado di controllare la risposta infiammatoria 
mediante produzione di IL-10 e induzione di apoptosi antigene-specifica, ha 
mostrato una diminuzione dell’espressione di PD-1 sui linfociti T CD4
+
 dei pazienti 
AD e MCI rispetto ai controlli sani.  
I risultati mostrano inoltre una diminuzione significativa della produzione di IL-10 da 
parte di CD14
+
PD-L1
+
. La down-regolazione di questi meccanismi osservata nei 
pazienti AD e MCI risulta in un aumento della proliferazione dei linfociti T stimolati 
alla βA. Il ruolo chiave svolto dall’interazione PD-1/PD-L1 nell’indurre l’apoptosi dei 
linfociti T CD4
+
 specifici per A è confermato dall’osservazione che l’apoptosi è 
bloccata preincubando queste cellule con un anticorpo bloccante anti- PD-L1.  
Lo studio delle sottopopolazioni linfocitarie nelle forme di AD rispetto alla forma 
MCI e agli HC ha inoltre evidenziato che nei pazienti AD non solo vi è 
un’alterazione nei meccanismi di tolleranza immunologica ma anche uno shift nel 
differenziamento del linfociti T verso un fenotipo infiammatorio di tipo Th-17 e Th-9. 
I risultati hanno, infatti, mostrato un aumento della produzione delle citochine 
infiammatorie (IL-21, IL-23, IL-6) e dei fattori di trascrizione (RORc/) coinvolti nel 
differenziamento dei Th-17 così come delle citochine effettrici (IL-21 e IL-22) 
prodotte da tali cellule nei pazienti AD rispetto agli MCI e agli HC. 
In particolare, IL-9, la citochina effettrice prodotta dalle Th-9, è significativamente 
aumentata nei pazienti AD, indicando che oltre ai Th-17 anche i Th-9 specifici per 
la beta-amiloide sono upregolati negli AD e Th-9 (IL-21 e IL-22). In conclusione la 
compromissione della risposta immunitaria, con una profonda inclinazione a favore 
di risposte effettrici e infiammatorie, sembra svolgere un ruolo chiave in questa 
patologia. 
III 
 
 
INDEX 
1. INTRODUCTION .................................................................................... 1 
1.1. The immune system ....................................................................... 1 
1.2. The adaptive immunity ................................................................... 1 
1.2.1. T cell subsets and functions .................................................... 2 
1.2.2. CD4 lymphocytes ...................................................................... 2 
1.2.2.1. Th-1 cells ......................................................................................... 2 
1.2.2.2. Th-2 cells ......................................................................................... 3 
1.2.2.3. Th-17 cells ....................................................................................... 3 
1.2.2.4. Th-9 cells ......................................................................................... 4 
1.2.2.5. Treg cells ......................................................................................... 5 
1.2.3. CD8 lymphocytes ...................................................................... 7 
1.2.4. B lymphocytes .......................................................................... 7 
1.3. Immunologic Tolerance .................................................................. 8 
1.4. The immune system in the Central Nervous System (CNS) ....... 10 
1.5. The immunology of neurodegeneration ...................................... 13 
1.6. Alzheimer’s Disease ..................................................................... 15 
1.6.1. History ..................................................................................... 15 
1.6.2. Introduction to the pathology ................................................ 16 
1.6.3. Symptoms of Alzheimer’s disease ........................................ 17 
1.6.4. Diagnosis of Alzheimer’s disease ......................................... 17 
1.6.5. Etiology of Alzheimer’s disease ............................................ 19 
1.6.5.1. Genetic ........................................................................................... 19 
1.6.5.2. Epigenetic ...................................................................................... 20 
1.6.5.3. The amyloid hypothesis ............................................................... 20 
1.6.5.4. Tau hypothesis ............................................................................. 23 
1.6.6. Therapies ................................................................................ 25 
1.6.6.1. Targeting A .................................................................................. 25 
1.6.6.2. Anti-tau therapies ......................................................................... 26 
IV 
 
1.6.6.3. Additional approaches ................................................................. 27 
1.7. Neuroinflammation in AD .......................................................... 27 
2. AIM OF THE STUDY ............................................................................ 31 
3. MATERIAL AND METHODS ................................................................ 32 
3.1. Flow cytometry principles ............................................................ 32 
3.2. Cell sorting .................................................................................... 33 
3.3. Patients and controls.................................................................... 34 
3.4. Blood sample collection and cell separation .............................. 35 
3.5. CFDA-SE labeling ......................................................................... 35 
3.6. Stimulation of PBMC for FACS analysis ..................................... 35 
3.7. Proliferation Assay ....................................................................... 35 
3.8. Cell purification ............................................................................. 36 
3.9. Suppression assays ..................................................................... 36 
3.10. Immunofluorescent staining ...................................................... 36 
3.11. Apoptosis .................................................................................... 37 
3.12. Blocking assay ............................................................................ 37 
3.13. Flow staining for PD-1 and FOXP3 of CD4+ CD25high T reg ...... 37 
3.14. Monoclonal Abs .......................................................................... 37 
3.15. Cytometric analysis .................................................................... 37 
3.16. Statistical analysis ...................................................................... 38 
4. RESULTS ............................................................................................. 39 
4.1. Treg cells in peripheral blood of AD or MCI patients and HC .... 39 
4.2. A pool-stimulated proliferation in AD, MCI and HC .................. 39 
4.3. Suppression of A pool and anti-CD3-stimulated proliferation by 
Treg ....................................................................................................... 40 
4.4. PD-1-expressing CD4+ and CD8+ T cells in A-stimulated PBMC
 .............................................................................................................. 40 
4.5. PD-L1-expressing CD14+ and CD19+ cells ................................... 40 
4.6. IL-10-secreting and PD-L1-expressing CD14+ and CD19+ cells . 41 
4.7. A-stimulated apoptosis and proliferation .................................. 41 
V 
 
4.8. CD4+ T helper subsets in A peptides-stimulated cell cultures . 42 
4.9. Cytokine-production in CD14+ cells in A-stimulated cell 
cultures ................................................................................................ 42 
4.10. Transcription factor-expressing CD4+ T cells in A peptide- 
stimulated cell cultures ....................................................................... 43 
4.11. Naïve and memory T cell subsets .............................................. 43 
5. DISCUSSION........................................................................................ 44 
6. CONCLUSIONS ................................................................................... 53 
7. BIBLIOGRAPHY .................................................................................. 55 
8. TABLES AND FIGURES ...................................................................... 83 
 
 
1. INTRODUCTION 
1.1. The immune system 
The immune system refers to a collection of cells and proteins that function to 
protect the organism from foreign antigens, such as microbes (organisms such as 
bacteria, fungi, and parasites), viruses, cancer cells, and toxins. The immune 
system consists of two “lines of defense”: innate immunity and adaptive immunity. 
Innate immunity represents the first line of defense to an intruding pathogen. It is 
an antigen-independent (non-specific) defense mechanism that is used by the host 
immediately or within hours of encountering an antigen. The innate immune 
response has no immunologic memory and, therefore, it is unable to recognize or 
“memorize” the same pathogen should the body be exposed to it in the future. 
Adaptive immunity, on the other hand, is antigen-dependent and antigen-specific 
and, therefore, involves a lag time between exposure to the antigen and maximal 
response. The hallmark of adaptive immunity is the capacity for memory, which 
enables the host to mount a more rapid and efficient immune response upon 
subsequent exposure to the same antigen.  
Innate immunity provides the first line of defense but also direct T cells of the 
adaptive immunity.  
The primary function of innate immunity is the recruitment of immune cells to sites 
of infection and inflammation through the production of cytokines (small proteins 
involved in cell-cell communication). Cytokine production leads to the release of 
antibodies and other proteins and glycoproteins which activate the complement 
system, a biochemical cascade that functions to identify and opsonize (coat) 
foreign antigens, rendering them susceptible to phagocytosis (process by which 
cells engulf microbes and remove cell debris). The innate immune response also 
promotes clearance of dead cells or antibody complexes and removes foreign 
substances present in organs, tissues, blood and lymph. It can also activate the 
adaptive immune response through a process known as antigen presentation [1,2]. 
Innate immunity can be viewed as comprising four types of defensive barriers: 
anatomic (skin and mucousmembrane), physiologic (temperature, low pH and 
chemical mediators), endocytic and phagocytic, and inflammatory. Cells of the 
innate immunity are neutrophils, mononuclear phagocytes, dendritic cells (DCs), 
mast cells, basophils, eosinophils, natural killer (NK) cells and lymphocytes (T 
cells). 
1.2. The adaptive immunity 
Adaptive immunity has evolved to provide a broader and more finely tuned 
repertoire of recognition for both self- and non self-antigens. In fact, the primary 
function of the adaptive immune response is the recognition of specific “non-self” 
antigens in the presence of “self” antigens. Adaptive immunity involves a tightly 
regulated interplay between antigen presenting cells (APCs) and T and B-
lymphocytes, which facilitate pathogen-specific immunologic effector pathways, 
generation of immunologic memory, and regulation of host immune homeostasis. 
Cells of the adaptive immune system include the effectors of cellular immune 
responses, the T lymphocytes, which mature in the thymus, and antibody- 
producing cells, the B-lymphocytes, which arise in the bone marrow. Lymphocytes 
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are highly mobile. After developing in the primary lymphoid organs (thymus and 
bone marrow), they traffic to secondary lymphoid organs, including lymph nodes 
and the spleen, which serve to capture circulating antigens from lymph and blood, 
respectively. Adaptive immune responses originate in these areas, often under the 
influence of innate immune system signals provided either directly by circulating 
pathogens or indirectly by pathogen-activated cutaneous or mucosal APCs 
migrating to the secondary lymphoid organs.  
1.2.1. T cell subsets and functions 
T cells elicit different effector functions in response to their activation. T cells can 
directly eliminate pathogens by killing infected target cells. They can function as 
helper cells, providing cognate (involving direct cellular contact) or cytokine signals 
to enhance both B- and T-cell responses, as well as causing activation of 
mononuclear phagocytes. Finally, T cells regulate immune responses, limiting 
tissue damage caused by autoreactive or unduly inflammatory immune responses. 
Mature T cells are activated on interaction of their T cell receptors (TCRs) with 
antigenic peptides complexed with major histocompatibility complex (MHC) 
molecules. CD8
+
 T cells can interact with peptides (9-11 amino acids in length) on 
almost any cell expressing MHC class I (HLA-A, HLA-B, and HLA-C). These MHC 
class I-restricted peptides are generally produced from proteins translated within 
the cell (endogenous antigens) encoded either in the host genome or by infecting 
viruses or other pathogens replicating intracellularly. In contrast, the TCRs of CD4
+
 
T cells engage peptides bearing MHC class II (HLA-DR, HLA-DQ, and HLA-DP). 
Unlike MHC class I expression, which is constitutive in all nucleated cells, MHC 
class II molecules are present on APCs and are inducible by innate immune 
stimuli, including ligands for Toll-like receptors (TLRs). APCs are specialized 
detectors of environmental antigens and danger signals (ligands for TLR and other 
systems of pattern-recognition receptors). T-cell activation is initiated when the 
TCR and associated proteins recognize a peptide/MHC complex on an APC, 
leading to a rapid clustering of TCR-associated molecules at the physical interface 
between T cells and APCs and the formation of a so called immunologic synapse 
[3]. 
1.2.2. CD4 lymphocytes 
The largest group of T cells in the body is the CD4
+
 population. Most of these cells 
serve a helper function and have been designated T helper cells (Th). Th cells play 
an important role in establishing and maximizing the immune response. These cells 
have no cytotoxic or phagocytic activity, and cannot kill infected cells or clear 
pathogens. However, they “mediate” the immune response by directing other cells 
to perform these tasks. Th cells are activated through TCR recognition of antigen 
bound to class II MHC molecules. Once activated, Th cells produce a range of 
cytokines.  
1.2.2.1. Th-1 cells 
About 20 years ago, immunologists Robert Coffman and Tim Mossman first 
discovered that not every single CD4
+
 Th cell has the capacity to produce the full 
range of cytokines known to be in the T-cell repertoire [4]. They demonstrated two 
main categories of Th cells, both Th-1 and Th-2 cells, each producing (mostly) 
mutually exclusive panels of cytokines. Th-1 cells were characterized by their 
capacity to make interferon (IFN)-, which activates the bactericidal activities of 
3 
 
macrophages, and other cytokines that induce B cells to make opsonizing (coating) 
and neutralizing antibodies, and IL-2 and were shown to differentiate from naive 
Th-0 precursors under the influence of IL-12 and IFN- and the T-box expressed in 
T cells transcription factor (T-bet).  
Th-1 cell cytokines drive cell-mediated responses, activating mononuclear 
phagocytes, NK cells, and cytolytic T cells for killing of intracellular microbes and 
virally infected targets. 
1.2.2.2. Th-2 cells 
Th-2 cells are producers of IL-4, IL-5, IL-10, and IL-13, which are involved in the 
activation and/or recruitment of immunoglobulin E (IgE) antibody-producing B cells, 
mast cells and eosinophils, and their development is driven by IL-4 and the 
transcription factor GATA-3. Th-1 cell cytokines drive cell-mediated responses, 
activating mononuclear phagocytes, NK cells, and cytolytic T cells for killing of 
intracellular microbes and virally infected targets. The Th-2 cytokine profile 
enhances antibody production, as well as a number of aspects of hypersensitivity 
and parasite-induced immune responses.  
Nowadays it is known that there is more plasticity to T-cell production of Th-1 and 
Th-2 cytokines than the constraints of the Th-1/Th-2 paradigm would suggest; thus, 
overlapping cytokine expression profiles are possible. In recent years, strong 
evidence for additional Th diversity has arisen [5].  
1.2.2.3. Th-17 cells 
Th-17 cells were established as an independent subset of T helper cells by the 
identification of differentiation factors and transcription factors that are unique to 
Th-17 cells. Th-17 cells secrete the cytokine IL-17 [6] and were, in fact, named for 
this purpose. In addition to secretion of IL-17, which is now known to include a 
family of similar proteins (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F), Th-
17 cells secrete IL-9 [7], IL-21 [8], IL-22, IL-26, and CCL20 [9]. Th cells in general 
are now recognized to be able to switch patterns of cytokine production, and Th-17 
cells in particular exhibit a high degree of plasticity in terms of cytokines produced, 
a property that is dependent on the surrounding cytokine milieu [10]. The plasticity 
of Th-17 cells remains an area of active investigation, and some Th-17 subsets, at 
least in humans, share features with Th-1 cells, suggesting a close developmental 
relationship between the two [11]. 
Th-17 differentiation requires multiple cytokines including IL-6, TGF-IL-21 and IL-
23 [12] and is dependent on the expression of the transcription factor RORc/  
[13,14].  
Th-17 cells play an important role in clearance of extracellular bacteria and fungi 
that are not adequately handled by Th-1 or Th-2 cells.  
Most experimental evidence to date suggests a role for IL-17 in local tissue 
inflammation, mainly via the induced release of pro-inflammatory cytokines and 
chemokines. In addition to cytokines and chemokines, IL-17 has also been shown 
to induce the production of other genes, including growth factors, antimicrobial 
peptides and MMP (matrix metalloproteinase) enzymes in epithelial cells, 
endothelial cells, fibroblasts, osteoblasts, macrophages and DCs [15,16]. 
A number of studies have shown that IL-17 induces tissue inflammation through 
stimulating pro-inflammatory cytokines. IL-17 also induces the production of other 
pro-inflammatory cytokines, such as tumor necrosis factor (TNF)- and IL-1 [17], 
and in turn synergizes with them to induce a large amount of inflammatory factors. 
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In addition to contributing to inflammatory pathogenesis, IL-17 is also critical for 
host defence.  
Th-17 cells play important role also in inflammation and autoimmune diseases; 
accordingly, elevated levels of IL-17 were detected in several autoimmune 
diseases including multiple sclerosis (MS), rheumatoid arthritis (RA) and psoriasis 
[18]. Before the discovery of the Th-17 subset, it was considered that Th-1, Th-2 
and B-cells were the main mediators of pathology in autoimmunity. Following the 
discovery of IL-17 and its biological functions, many studies have demonstrated 
that increased IL-17 expression is associated with inflammatory autoimmune 
diseases in either human patients or animal disease models [12,19]. 
Robust evidence shows that IL-17 mediates adverse effects in many autoimmune 
diseases such as RA, MS, systemic lupus erythematosus (SLE), inflammatory 
bowel disease (IBD) and psoriasis to name a few [20]. 
1.2.2.4. Th-9 cells 
Of significant importance is the recent discovery of Th-9 cells, the CD4
+
 T cell 
subset that produces IL-9. IL-9 has largely been regarded as a Th-2 cytokine; 
however, it is now known that under specific conditions, Tregs, Th-1, Th-17 and the 
Th-9 subset of T cells also produce IL-9. The functional diversity of Th cell subsets 
is chiefly based on specific cytokines, and their development from naive CD4
+
 T 
cells relies on distinct cytokine signals that initiate differentiation by either 
transactivation or repression of subset-specific transcription factors. Upon 
activation by APCs in the presence of TGF- and IL-4, naive CD4
+
 T cells 
differentiate into Th-9 cells that are characterized by expression of high amounts of 
IL-9, as well as IL-10. However, Th-9 cells don’t coexpress the cytokines IL-4, IL-5, 
IL-13 (Th-2), IL-17a (Th-17), or IFN- (Th-1) upon activation [21,22]. And despite 
their ability to produce high amounts of IL-10, no regulatory properties of Th-9 cells 
have been described thus far [21]. Accordingly, Th-9 cells do not express subset-
determining transcription factors like T-bet (Th-1), GATA-3 (Th-2), RORc/t (Th-
17), or FOXP3 (Treg cells) at levels comparable to the respective T cell subsets, 
indicating that Th-9 cells are an autonomous Th cell subset. 
As suggested by the patterns of receptor expression, IL-9 has biological effects on 
a number of distinct cell types. Beyond the first description as T cell or mast cell 
growth factor, IL-9 may affect other immune cells, as well as resident tissue cells 
that contribute to the development of inflammation. 
The role of Th-9 cells in human pathology is still controversial even if recent 
evidences suggest their involvement in allergic and autoimmune diseases [23,24]. 
Th-9 cells are pro-inflammatory, but appear to function in a broad spectrum of 
autoimmune diseases and allergic inflammation. Their precise function likely 
depends upon the tissue microenvironment and other T helper cell cytokines that 
are present in the inflammatory milieu. Th-9 cells contribute to inflammation in 
several autoimmune disease models. Th-9 cells induce inflammation in a T cell 
transfer colitis model [21]. Mice that received Th-9 cells only, lost weight and 
developed a moderate colitis. Moreover, mice that received effector T cells 
together with Th-9 cells developed a more severe colitis. A similar pro-inflammatory 
role of Th-9 cells was demonstrated in an Experimental autoimmune 
encephalomyelitis (EAE) model [24]. Myelin oligodendrocyte glycoprotein (MOG)-
specific naive CD4
+
 T cells were differentiated in vitro under Th-1, Th-2, Th-17 and 
Th-9 polarizing conditions before adoptive transfer. All mice that received Th-9 
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cells developed severe EAE and lesions in the CNS. Cells in the CNS of Th-9 
recipients retained IL-9 producing capacity, but also produced IFN-. Although Th-
1, Th-17 and Th-9 cells induced EAE with similar severity, differences in CNS 
pathology suggested Th-9 cells promote inflammation through distinct 
mechanisms. 
Th-9 cells also contribute to allergic inflammation and disease. IL-9 is highly 
expressed in the lungs of asthmatic patients [25,26].  
1.2.2.5. Treg cells 
Human regulatory T cells (Tregs) were first isolated from peripheral blood and 
characterized as CD4
+
CD25
high
 T cells by several groups in 2001. The transcription 
factor forkhead box P3 (FOXP3) is the canonical, specific marker for human Tregs 
and is thought to serve as the ‘master regulator’ in charge of Treg development 
and function. Recent studies have shown that human CD4
+
FOXP3
+
 T cells are not 
homogeneous in gene expression, phenotype and suppressive functions, and 
indicate that new basis for reliable delineation of human Treg cells is required. 
These cells include different functional and phenotypic subpopulation. 
CD4
+
/CD25
high
/FOXP3
+
 Treg cells can be sub-classified based on the surface 
expression of programmed death receptor-1 (PD-1 or CD279). PD-1 can either be 
retained within the intracellular compartment, or it can be expressed on the 
surface, upon activation. Treg cells that retained PD-1 in the intracellular 
compartment are endowed with stronger suppressive properties and are defined as 
PD-1
neg
 [27]. 
Current dogma dictates that all these mechanisms of suppression mediated by 
Treg cells require a direct contact cell-to-cell to mediate their inhibitory activity. This 
has been upheld by in vitro experiments where Treg cells are unable to suppress 
effector T cell proliferation when the two populations are separated by a permeable 
membrane [28]. Several T-cell accessory molecules, such as CTLA-4 (CD152) and 
lymphocyte-activation gene 3 (LAG3), expressed by Tregs, and CD80 and CD86 
costimulatory molecules expressed by APCs contribute to this contact-dependent 
suppressive mechanism [29].  
Many potential suppression mechanisms of Treg cells have been hypothesized: 
suppression by the secretion of inhibitory cytokines, such as IL-10 and TGF-
suppression by cytolysis, through the release of perforin and granzyme A, which 
might induce death of T cells, monocytes and DCs, and suppression by modulation 
of DC maturation or function, by the interaction of CTLA-4, expressed constitutively 
on Treg cells, with CD80 and CD86, expressed by DCs. Many reports indicate that 
cytokines such as IL-10 and TGF- are needed in vivo for mediating suppression 
or conditioning a suppressive milieu. Several in vivo experiments support the role 
of IL-10 in Treg suppression. It has recently been demonstrated that FOXP3
+
 Tregs 
in intestinal lamina propria or in the CNS could control colitis and EAE, 
respectively, by local secretion of IL-10 [30,31]. A support of the important 
contribution of TGF- to Treg suppression derives from animal models, in which 
natural Tregs isolated from neonatal TGF- knockout mice exhibit a normal 
suppressive activity in vitro and can prevent inflammatory bowel disease in vivo 
[32]. 
Tregs might kill effector cells, as another mechanism of Treg-mediated 
suppression. The release of perforin and granzyme A might induce death of T cells, 
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monocytes and DCs. The release of granzyme B might kill T cells and B cells in a 
perforin-independent and perforin- dependent way, respectively [33-35]. 
CD25
+
CD4
+
 natural Tregs constitutively express CTLA-4, whereas naive T cells 
express this molecule only after activation. These results suggest several possible 
roles for CTLA-4 in Treg-mediated suppression. One is that CTLA-4 on Tregs 
might interact with the CD80 and CD86 molecules on APCs and transduce a co-
stimulatory signal to Tregs (i.e. signals via both CTLA-4 and TCR might activate 
Tregs to exert suppression). CTLA-4 blockade therefore prevents Treg activation 
and, hence, attenuates suppression, causing autoimmune disease. This blockade 
might also enable interaction between CD28 molecules expressed by Tregs and 
CD80 and CD86 less competitively and, hence, more easily transduce a 
suppression-attenuating signal to Tregs, because strong ligation of the CD28 
molecules together with TCR stimulation can abrogate Treg-mediated suppression. 
Another possible role of CTLA-4 for Treg function is that it might directly mediate 
suppression. CTLA-4 expressed on Tregs triggers induction of the enzyme 
indoleamine 2,3- dioxygenase (IDO) in DCs by interacting with their CD80 and 
CD86. IDO catalyzes the conversion of tryptophan into kynurenine and other 
metabolites, which have potent immunosuppressive effects in the local 
environment of DCs by means of cytotoxicity or possibly by inducing de novo 
generation of Tregs from naive CD25
-
CD4
+
 T cells [36]. 
The primary function of Treg cells was originally defined as prevention of 
autoimmune diseases by maintaining self-tolerance [37]. Over the years, several 
additional functions have been suggested and it will be important to clarify what 
Treg cells actually do in the immune system. Presently several functions have been 
proposed for Treg cells: 
 Prevention of autoimmune diseases by establishing and maintaining 
immunologic self-tolerance and immune homeostasis [37,29]; 
 Suppression of allergy and asthma [38,39];  
 Induction of tolerance against dietary antigens, i.e. oral tolerance [40-42]; 
 Induction of maternal tolerance to the fetus [43]; 
 Suppression of pathogen-induced immunopathology [44,45]; 
 Protection of commensal bacteria from elimination by the immune system [46]; 
 Suppressive control against autologous tumour cells [47];  
 Induction of tolerance in allogeneic organ transplants [48]; 
Treg cells can suppress activation, proliferation and effector functions like the 
production of cytokines of a wide range of immune cells, including CD4
+
 and CD8
+
 
T cells, NK and NKT cells, B cells and APCs in vitro and in vivo [49,50]. FOXP3 
expressing Treg cells belong to a wide group of T cells that can suppress effector 
cell responses. These regulatory T cells include IL-10 secreting TR1 cells, TGF- 
producing Th-3 cells, / TCR expressing T cells and CD8
+
CD28
−
 T cells. Whereas 
most of these regulatory T cells are induced or adaptive i.e. they are naïve T cells 
that acquire a regulatory phenotype and function upon activation in the periphery 
under particular situations such as particular antigenic stimulation or particular 
cytokine milieus, FOXP3
+
 Treg cells are naturally occurring regulatory T cells that 
are developmentally programmed under the control of the transcription factor 
FOXP3 in the thymus [51]. 
As a consequence, loss of Treg function appears to be a fundamental factor in 
autoimmunity [52]. 
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1.2.3. CD8 lymphocytes 
CD8
+
 T cells represent a major fraction of circulating T cells and act to remove both 
cells harboring intracellular pathogens, including viruses and transformed cells. 
Because CD8 serves as a co-receptor for MHC class I CD8
+
 T cells primarily 
recognize antigenic peptides derived from cytosolic proteins. Cytolytic T 
lymphocytes (CTLs) kill target host cells in a contact-dependent mechanism. 
Recognition of foreign cytosolic peptides of the target cell in the context of host 
MHC class I by the CTL TCR leads to the formation of a conjugate with an 
immunologic synapse. Within minutes, the CTL activates apoptotic cell death in the 
target cell. This process is mediated by rapid mobilization of CTL granules to the 
synapse followed by fusion of granule membranes with the target cell plasma 
membrane and exocytosis of granule contents, including granzymes and perforin. 
The granzymes are serine proteases that target a number of proteins in the host 
cell, leading to activation of apoptosis. In a parallel proapoptotic pathway, TCR 
activation in the immune synapse drives expression of Fas ligand on the CTL. This 
in turn engages Fas (CD95) on the target cell membrane, again triggering 
apoptosis. 
1.2.4. B lymphocytes 
Adaptive humoral immunity is mediated by antibodies produced by plasma cells 
that develop from B cells under the direction of signals received from T cells and 
other cells, such as dendritic cells. B cells arise from hemopoietic stem cells in the 
bone marrow. Unlike T cells, B cells can recognize free antigen directly, without the 
need for APCs. The principal function of B cells is the production of antibodies 
against foreign antigens [1]. Several subpopulations of B cells in peripheral blood 
can be distinguished based on surface-marker expression.  
The second phase of B-cell development occurs after encounter with antigen and 
activation and is called the antigen-dependent phase.  
Some antigens elicit antibody formation in the absence of T cells, and are called T-
independent (TI) antigens. Certain molecules, such as some plant lectins (eg, 
pokeweed mitogen), are alone capable of inducing proliferation and antibody 
production from mature B cells. These are called TI type 1 antigens [53]. Some 
macromolecules, such as polymerized proteins or polysaccharides, possess 
repeating molecular patterns that can interact with multiple immunoglobulin 
receptors on the cell surface and cross-link them. This might deliver a partially 
activating signal that can progress to memory or plasma cell development with only 
the additional signals provided by cytokines or other cell contacts provided by 
dendritic cells [54]. These are called TI type 2 antigens. In many cases the 
antigens themselves might also provide more than one activating signal because 
some might interact with other receptor systems, such as TLR [55]. 
The vast majority of antibody responses to proteins and glycoproteins require 
participation of T cells, and these antigens are called T dependent. Mature B cells 
recirculate through secondary lymphoid organs, including lymph nodes, the spleen, 
and mucosal-associated lymphoid tissues. Antigens complexed to varying to 
degrees with IgM, IgG, and complement might be carried on the surfaces of 
specialized macrophages, follicular dendritic cells, or even B cells themselves, all 
of which have receptors for IgG Fc and complement fragments. Antigen presented 
on these surfaces can stimulate B cells through immunoglobulin receptor cross-
linking, expression of other interacting surface molecules, and cytokine secretion. B 
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cells require two principal types of signals to become activated. Signal one is 
delivered by cross-linking of the immunoglobulin receptor, as described above. 
This cross-linking leads to activation of intracellular signaling pathways that render 
the cell capable of interacting with T cells and thereby receiving signal two.  
B cells are active as APCs and express peptides along with MHC class II on their 
surface. These peptides can arise from processed antigen that was internalized 
after binding to the B-cell surface immunoglobulin receptor. When the B cell 
contacts a CD4
+
 T cell specific for such a peptide with self-MHC class II and having 
been previously activated by an APC, the T cell is able to provide cognate (direct 
cellular contact) help and activate the B cell for further differentiation into memory 
cells or plasma cells. The activated B cells enter one of two pathways. Either they 
immediately become short-lived plasma cells secreting low-affinity antibody without 
somatic mutation, or they enter a follicle to establish a germinal center (GC)[56].
 
In 
the germinal center B cells can change from the production of IgM and IgD to other 
isotypes, such as IgG, IgA, and IgE. This process, called class- switching, occurs 
through a mechanism of gene rearrangement [1].  
1.3. Immunologic Tolerance 
The immune system must balance the need to maintain a diverse repertoire of 
lymphocytes to be able to fight infection with the need to maintain tolerance to self-
proteins. Immunologic tolerance is defined as unresponsiveness to an antigen that 
is induced by previous exposure to that antigen. Tolerance to self-antigens is a 
fundamental property of the immune system. Self-tolerance may be induced as a 
consequence of immature self-reactive lymphocytes recognizing self-antigens, 
called central tolerance, or in peripheral sites as a result of mature self- reactive 
lymphocytes encountering self-antigens under particular conditions, called 
peripheral tolerance.  
Central tolerance is established in the thymus by the elimination of autoreactive 
thymocytes that display a TCR with high affinity for self-peptide/MHC complexes 
[57]. Despite the relative efficiency of clonal deletion not all tissue-specific antigens 
are expressed in the thymus and thus a small proportion of autoreactive T cells can 
escape thymic deletion, complete their maturation and enter the peripheral 
circulation. The immune system has multiple checkpoints in place to limit the 
activation and expansion of these autoreactive cells in the periphery [58]. The last 
decade has led to an improved understanding of some of these checkpoints 
involved in peripheral regulation of the immune response. In the periphery the 
immune system has a range of mechanisms available that control the fate of 
autoreactive T cells, including immune privilege, immune ignorance, activation-
induced cell death, clonal anergy, and immune suppression-mediated byTreg cells 
[29,59,60].   
Anergy is a process that occurs when a T cell encounters its proper peptide under 
one of these particular conditions. A first condition is that the cell expressing the 
peptide on its surface is a non-professional APC. This cell type may possess the 
MHC niche for the peptide, which is therefore recognized by the TCR, but lacks the 
so-called co-stimulatory molecules, such as CD80 and CD86, which are able to 
provide an activatory signal to the T helper cell through their interaction with CD28. 
In the absence of this costimulatory signal, the T helper cell not only does not 
undergo activation, rather becomes unable to be activated even when it re-
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encounters the same peptide on the surface of professional APCs equipped with 
costimulatory molecules [61].  Another possibility is that peptide recognition by the 
T helper cells is followed by an interaction of the co-stimulatory molecules CD80 
and CD86 with the suppressive cytotoxic T lymphocyte associated antigen CTLA-4, 
instead of the activating CD28, molecule on the surface of the T helper cell. Under 
both these conditions, the T helper cell does not die and becomes functionally 
inactive.  
Deletion is another mechanism of peripheral tolerance of mature T cells, which is 
based on their apoptotic cell death [62]. This usually happens when T cells 
encounter high antigen concentrations or they are heavily activated. This process 
is known as “activation-induced cell death” (AICD) and is mediated through the 
high expression of the surface molecule Fas (CD95), as well as its ligand (FasL or 
CD95L). The interaction between Fas and of its ligand on the surface of the 
proliferating T helper cells activates the cascade of caspase enzymes that ends 
with the apoptotic cell death [63].   
The third mechanism of peripheral T-cell tolerance is represented by immune 
suppression achieved by Treg cells.   
Regulation through inhibitory molecules like PD-1 plays a critical role in the delicate 
balance between effective immunity and self-tolerance. 
 
PD-1 (CD279) is a member of the CD28 superfamily of immunoreceptors involved 
in regulating cell activation. PD-1 is a 55 KDa type 1 transmembrane protein that is 
upregulated on T cells, B cells, and some myeloid cells upon activation. Signaling 
through PD-1 limits T cell function, including IFN- production and proliferation [64-
66].  
PD-1 is an immunoglobulin (Ig) superfamily member that has an N-terminal IgV-like 
domain, an approximately 20 amino acid stalk separating the IgV-like domain from 
the plasma membrane, a transmembrane domain, and a cytoplasmic domain with 
an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor 
tyrosine-based switch motif (ITSM). The protein tyrosine phosphatases SHP-1 and 
SHP-2 can bind to the ITSM sequence in the PD-1 cytoplasmic tail. Binding of the 
ITSM by SHP-1 or SHP-2 results in the dephosphorylation of proximal signaling 
molecules and augmentation of phosphatases and tensin homolog (PTEN) 
expression. This effectively attenuates the activation of the phosphatidylinositol 3-
kinases (PI3K) and protein kinase B (Akt), which are key for glucose transport and 
glycolysis, so PD-1-mediated inhibition of these signaling molecules can hamper 
cell bioenergetics, resulting in decreased T-cell proliferation, survival, protein 
synthesis, and IL-2 production.  
PD-1 is expressed during thymic development and interacts with at least two 
ligands, programmed death-ligand 1 (PD-L1, CD274) and another closely related 
molecule, PD-L2 (CD273) [67-69]. PD-L1 was identified by searching for homologs 
of B7-1 (CD80) and B7-2 (CD86), the two ligands for CTLA-4 and CD28.  
The expression patterns of PD-L1 and PD-L2 are somewhat distinct. PD-L1 is 
expressed on T cells, B cells, DCs and macrophages, as well as several non-
hematopoietic cell types including vascular endothelial cells, pancreatic islets, 
astrocytes, and keratinocytes [70]. PD-L2, on the other hand, is expressed 
exclusively on DCs and monocytes [71]. The PD-1 ligands, PD-L1 and PD-L2, are 
constitutively expressed in peripheral tissue sites during homeostasis and become 
elevated in response to tissue insult and inflammation.  
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The costimulatory pathway consisting of PD-1 and its ligands, PD-L1 and PD-L2, 
delivers inhibitory signals that regulate the balance among T-cell activation, 
tolerance, and immune-mediated tissue damage [70,72-74]. This pathway exerts 
critical inhibitory functions in the setting of persistent antigenic stimulation such as 
during encounter of self-antigens, chronic viral infections, and tumors [70]. This 
pathway has a central role in regulating the interplay between host defenses aimed 
at eradicating microbial pathogens and tumors as well as microbial and tumor 
strategies that evolved to resist immune responses. The PD-1/PD-L1 pathway 
contributes directly to T-cell exhaustion and lack of viral control during chronic 
infections [75] as well as the suppressive tumor microenvironment  [76]. This 
pathway controls multiple tolerance checkpoints that prevent autoimmunity. To 
provide a context for these studies, we first introduce PD-1 and its ligands and 
discuss the roles of Tregs in peripheral tolerance and autoimmunity. 
PD-1/PD-L1 interactions result in the up-regulation of IL-10 production, reduction of 
T cell proliferation and the induction of apoptosis of antigen- specific cells [64,69, 
77]; thus they play a substantial role in regulating autoreactive T cells that are 
specific for tissue-restricted self-antigens. PD-L1 and PD-1 are both expressed on 
CD4
+
CD25
+
 T cells. The compartmentalization of PD-1 allows to discriminate 
between two Treg sub-population: Raimondi and colleagues observed that 90% of 
Treg (positive for the nuclear transcription factor FOXP3 and able to inhibit naive T 
cell proliferation), isolated from the spleens or lymph nodes of normal mice, did not 
express significant levels of the inhibitory receptor PD-1 on their surface, but 
retained PD-1 inside the cell. An identical phenotype was also identified for human 
resting CD4
+
CD25
high
 T cells isolated from peripheral blood of healthy volunteers. 
By contrast, activated T cells expressed high levels of surface PD-1 that paralleled 
up-regulation of CD25 during effector cell expansion [27]. 
1.4. The immune system in the Central Nervous System (CNS) 
Several features make the brain’s immune system different: the presence of the 
Blood-Brain Barrier (BBB), a minimal number of T cells, limited numbers of cells 
which constitutively express MHC class I and MHC class II and therefore have 
limited ability to trigger T cell responses, and the lack of a lymphatic system. In 
addition, it is argued that microglia, even when activate, are poor APC [78]. 
However, the continuous sampling of the tissue by microglia ensures constant 
monitoring, and the ability of these cells to respond to any threat to homeostasis, 
has led to the acceptance that there is a continuing low-level inflammatory activity 
in the CNS which is primarily concerned with repair.  
A range of insults including genetic, autoimmune, infectious, or neurodegenerative 
diseases and cancer may affect tissues of the CNS, such as the brain, optic 
nerves, and spinal cord. The immune system is involved in the pathogenesis of 
many of these diseases, either by causing tissue damage or alternatively by 
responding to disease and contributing to repair. In contrast to other tissues, 
damage caused by immune pathology in the CNS can be irreparable. The nervous 
and immune systems have, therefore, coevolved to permit effective immune 
surveillance while limiting immune pathology.  
The parenchyma of the normal brain and spinal cord has a limited capacity for 
antigen processing and presentation, since it contains few professional APCs and 
neurons only express MHC under exceptional conditions [79]. The immune 
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response is also delayed since lymphocytes have to be activated before they can 
cross the BBB [80], and even then this transmigration process is arduous. Once 
lymphocytes have been activated, microglia, the innate immune cells of the CNS, 
further respond to inflammation by upregulation of immunoregulatory molecules 
including B7-H1 [81] and IDO [82], while neurons protect themselves by secreting 
TGF- upon contact with activated lymphocytes [83].  
The non-inflamed brain is protected by vascular endothelium at the BBB and by 
glia limitans, formed from parenchymal basement membrane and astrocytic foot 
processes. Nevertheless, CSF from individuals with no inflammatory neurological 
disease contains about 150,000 T lymphocytes [84]. The T cells in human CSF are 
mainly effector memory (CD45RA
-
, CD27
+
, L-selectin 
high
), and the majority is CD4 
positive [85]. This phenotype permits trafficking through extralymphoid tissue as 
well as subsequent return to the lymphatic system via high-endothelial venules. 
Activated lymphocytes make formal contact with the BBB via 4-integrin and 
endothelial VCAM-1 [86] and cross the barrier by diapedesis. This is a difficult 
process, especially in the non-inflamed CNS, although entry to the leptomeningeal 
compartment can occur more readily in a P-selectin- dependent manner [87]. Even 
then, entry to the CNS parenchyma is dependent on further encounter with 
cognate antigen. If antigen is seen, then the immune cells mount an inflammatory 
response, draw other immune cells into the specific site, and then collectively 
breech the glia limitans to infiltrate the parenchyma.  
Lymphocyte migration into and within the CNS is regulated by chemokines and 
their receptors. The BBB plays a key role in modulating entry of solutes and ions 
into the CNS and, although migration of cells appears to be controlled to a 
significant extent by expression of chemokines and adhesion molecules and their 
receptors, infiltration of circulating cells occurs during chronic neuroinflammation 
when release of inflammatory mediators from activated microglia increases BBB 
permeability [88]. Without concomitant inflammation, CD4
+
 migration outside of 
blood vessels is constrained to pathways that run along their axes [89] and is 
different from the random motility of CD8
+
 cells [89-91]. This confinement is 
regulated by the interaction of the chemoattractant CXCL12 with the receptor 
CXCR4, expressed on the surface of lymphocytes. The migration of leukocytes into 
the CNS may be modulated by sequestration of CXCL12 by other receptors, or by 
the physical redistribution of CXCL12 that occurs in MS and the disease model 
EAE [90,91]. In addition, blockade of CXCR4 allows CD4 T cells to escape from 
their perivascular containment and penetrate deeper into brain parenchyma 
[89,90]. Collectively these mechanisms ensure that immunosurveillance within the 
normal CNS occurs at a slower pace than in the periphery and is biased to recently 
activated CD4
+
 cells with a phenotype that allows them to traffic back to secondary 
lymphoid tissue once they leave the nervous system. However, immune 
surveillance of the CNS is a critical mechanism, as illustrated recently by the 
observation of complications associated with antibody therapies for MS that block 
this process. 
Although it is fundamentally different from the peripheral immune system in many 
respects, the immune system of the CNS robustly defends the integrity of the 
tissue and is vital for the maintenance of homeostasis. Dysregulation of the 
mechanisms that control inflammatory activity is the most likely cause of 
pathological inflammation and the consequent neurodegeneration.  
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The reparative function of the immune response occurs under non-pathological 
conditions but also in response to insults, infection, injury and inflammation and it 
could be compromised with age, resulting in neurodegeneration and chronic 
neuroinflammation. The brain also protects itself by maintenance of an 
immunosuppressive environment, due to soluble factors released by neurons and 
astrocytes, but also as a consequence of neuronal expression of 
immunosuppressive proteins like CD200, CD47, CD22 and fractalkine (CX3CL1), 
which interacts with its receptor on microglia and maintains microglia in a quiescent 
state. Released soluble factors which downregulate immune responses include 
neurotrophins, anti-inflammatory cytokines like TGF- (which downregulates 
endothelial expression of adhesion molecules required to allow entry of peripheral 
cells into the brain), and anti-inflammatory prostaglandins. Many of these unique 
features are broken down by chronic inflammation. Predictably T cell infiltration has 
been found in CNS tissues of Parkinson’s Disease (PD) patients [92], where 
evidence of neuroinflammation is accompanied by increased BBB permeability [93] 
and similar correlative changes are found following ischemic insult and with age 
[88] and bacterial and viral infections [94].  
BBB permeability is also increased by amyloid-beta (A) [95] and consequently the 
presence of T cells in brain as well as increased T cell reactivity have been 
reported in patients with Alzheimer’s disease (AD) [96]. Interestingly T cells 
obtained from AD patients express increased CXCR2 and macrophage 
inflammatory protein-1a (MIP-1a), which enhance T cell migration into brain 
[97,98]. The presence of T cells in the brain has the capacity to profoundly affect 
glial function. Microglial cells are considered to be the immune effector cells in the 
CNS, belonging to the mononuclear phagocytic system.  
Microglial cells constitute about 10% of adult CNS cell population and represent the 
innate immune system of the brain. They generate an antigen-non-specific 
response to injury and diverse endogenous and exogenous stimuli. Microglial cells 
constitute the first barrier and immune sentinels, being distributed through brain 
parenchyma continuously for sensing their microenvironment and producing pro- 
and anti-inflammatory cytokines. Microglia predominate in gray matter, with the 
highest concentration in hippocampus and substantia nigra [99,100]. 
They express proteins characteristic of professional phagocytes and immune cell 
members such as complement components and their receptors, MHC 
glycoproteins, and scavenger receptors. 
Microglial cell populations are heterogeneous within different regions of the brain 
[101]. 
Resident microglia, the innate immune system occupants of the CNS, are one of 
two populations of myeloid immune cells (the other being monocyte derived 
macrophages) that are activated under a neurodegenerative milieu. Under 
physiological conditions, microglia is engaged in immune surveillance and host 
defense [102]. These cells are particularly sensitive to changes in their 
microenvironment and readily become activated in response to infection, trauma, 
disease and tumors. Once activated, microglia mainly operates as scavenger cells, 
producing a wide spectrum of molecules that are essential for the elimination of 
invading pathogens and the clearance of toxic factors (such as the aggregated 
misfolded proteins found in AD) and cellular debris. Moreover, these cells, under 
pathological conditions and in their semiquiescent state, produce a myriad of 
factors (including neurotrophic, growth and neural survival factors) that are pivotal 
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for tissue maintenance, repair and renewal [102]. The second population of 
myeloid derived cells found in the CNS is the infiltrating monocyte- derived 
macrophages, which, under pathological conditions, are recruited in the CNS, 
infiltrate the brain parenchyma from the circulatury system and differentiate in 
macrophages. 
Summarizing, two populations of microglia can be distinguished. One, which is 
short-lived and frequently replaced from circulating monocyte-macrophages 
sources, is concentrated in perivascular and some specific parenchyma regions. 
The second population, which is long-lived, is resident and abundant in all the CNS 
parenchyma [103,104]. 
Microglial cells that are basally quiescent are characterized by a small cell body 
and ramified processes. When activated in response to many stimuli, they undergo 
morphological changes that include enlargement of the cell body and shortening of 
cellular processes. Besides, microglial cells response is characterized by 
phagocytosis, T-helper cell Th-2 induction and by secretion of IL-4, IL-10 and TGF-
. Th-2-activated cells produce IL-4, IL-6, IL-10 and IL-13, cytokines that promote 
humoral immune responses and down-regulate Th-1-mediated responses, 
inhibiting numerous macrophage inflammatory functions [105]. The activated state 
of microglial cells, far from a single phenotype, represents a continuum change 
from innate to adaptive activation with the expression of different cytokines and 
cytokine receptors that modulate T cell response [105]. In activated state, 
microglial cells up regulate the expression of different cell surface activation 
antigens, pattern recognition receptors (PRRs), produce cytokines and secrete 
short-lived potentially cytotoxic species such as nitric oxide (NO) and reactive 
oxygen species (ROS) [106]. Glial activation results in diverse functional effects 
including proliferation, up-regulation of active molecules, release of cytokines and 
growth factors, phagocytic transformation and production of NO and ROS. 
Whereas early stages of an inflammatory response can protect neurons [107], 
chronic inflammation and the subsequent activation of microglia become 
detrimental [108-110]. Chronically primed microglia exhibit more rapid induction 
and an exaggerated pro-inflammatory cytokine release, enhancing for example 
sickness behaviour induced by lipopolysaccharide (LPS), and suggesting that 
aging microglia are over-responsive [111-113]. 
1.5. The immunology of neurodegeneration 
Despite intensive study over the past three decades, neurodegenerative diseases 
remain insufficiently understood, precluding rational design of therapeutic 
interventions that can reverse or even arrest the progressive loss of neurological 
function. Several theories investigating the causes of neurodegenerative diseases 
have been formulating such as those involving a central role for protein misfolding, 
mitochondrial dysfunction, oxidative damage to lipids, proteins and nucleic acids, 
excitotoxicity, and transcriptional dysregulation. Neurodegeneration ultimately 
targets neurons and can range from damage to synapses or neurites to cell death. 
Once a danger signal is detected, neurons can activate intracellular defense 
mechanisms and can alert neighboring cells via cell-cell interactions or the release 
of signaling proteins, neurotransmitters, and other messengers. When neurons 
send out distress signals, there is a strong response from CNS-resident immune 
cells such as microglia. What is most confusing about this response is that rather 
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than helping the injured neurons, more often than not microglia seems to harm or 
kill neurons. 
The observation that all neurodegenerative diseases are associated with activated 
innate immune cells have led inflammation to be considered as a promising 
therapeutic target for Alzheimer’s Disease and other neurodegenerative conditions 
[114]. Most of neurodegenerative diseases are, infact, characterized by glial 
activation, which is responsible for chronic inflammation observed in these 
diseases.  
The altered activation state of glia, particularly microglia, is an indicator of chronic 
immune activation and of the reduced ability of the brain’s immune system to 
restore homeostasis. Activated microglia produces several neurotoxic molecules, 
including ROS, glutamate, and inflammatory cytokines, such as TNF and IL-1, 
which differentially induce neurotoxicity.  
Chronic neuroinflammation can lead to cell dysfunction triggering a self-
perpetuating cycle of damaging events driving pathogenic processes and 
consequently neurodegeneration. Degenerating cells, particularly neurons, are an 
integral part of this self-destructive cycle releasing danger-associated molecular 
patterns (DAMPs), like ATP and high mobility group protein 1 (HMGB-1), and 
these, by interacting with toll-like receptors and other pathogen recognition 
receptors (PRRs), trigger inflammatory changes. Other DAMPs include 
aggregated, modified or misfolded proteins for instance amyloid-, tau and -
synuclein, which accumulate in Alzheimer’s disease and/ or Parkinson’s disease. 
Although inflammation may not typically represent an initiating factor in 
neurodegenerative disease, there is emerging evidence in animal models that 
sustained inflammatory responses involving microglia and astrocytes contribute to 
disease progression.  
Chronic microglial production of pro-inflammatory cytokines including interleukins 
(IL-1 and IL-6), TNF-, and IFN- has received considerable attention for its role in 
neurodegenerative disorders.  
A number of pathologic events, including altered neuronal function, injury, infection 
ischemia, and inflammation, can activate microglia. This activation results in a 
transition in microglial morphology to an ameboid state facilitating the migration of 
these cells to the site of insult [115]. Microglial response to CNS pathology also 
results in initiation of a number of immune functions including phagocytosis, 
antigen processing and presentation, and production of both cytotoxic and 
neurotrophic factors [115,116]. Microglial actions may be dependent on the nature 
of the activating stimulus. Stimulation of microglia with LPS, amyloid protein, and 
high concentrations of IFN-determines the release of several mediator of 
cytotoxity including reactive oxygen and nitrogen species, arachidonic acid 
metabolites (eicosanoids), excitotoxic glutamate, quinolic acid, and histamine [117]. 
Alternatively, exposure to IL-4 and low levels of IFN- lead to microglial release of 
neurotrophic factors including nerve growth factor (NGF), brain derived 
neurotrophic factor (BDNF), and neurotrophin-4/5 (NT-4/5) [118].  
While short-term microglial activity is generally accepted to serve a neuroprotective 
role, chronic activation has been implicated as a potential mechanism in 
neurodegenerative disorders. A special emphasis has recently been placed on 
microglial release of pro-inflammatory cytokines including IL-1, IL-6, TNF-, and 
IFN- and their roles in neuronal degeneration. 
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It is important to note, however, that microglia are not the sole producers of 
cytokines following CNS insult. Astrocytes have also been implicated in the 
generation of pro-inflammatory mediators involved in neurodegenerative disorders 
[119]. 
While this neuroinflammatory response may be beneficial for clearing infection and 
initiating tissue repair mechanisms, if left unresolved, it exposes sensitive neurons 
to elevated levels of potentially toxic molecules, leading to bystander injury. In fact, 
there is mounting evidence that chronic neuroinflammation plays a critical role in 
the pathoetiology of various neurodegenerative diseases including Alzheimer's 
disease, multiple sclerosis, and Parkinson's disease [105,120, 115]. 
Astrocytes are the most abundant glial cell in the in the central nervous system and 
play multiple roles in organizing and maintaining brain structure and function [121]. 
Although activated astrocytes provide neuroprotection by the release of 
neurotrophic factors, they also participate in inflammatory reactions expressing pro-
inflammatory molecules, such as cytokines and chemokines  [122,123]. Hence, if 
astrocytes malfunction, the result can be disturbances in homeostasis that could 
potentiate neurodegenerative diseases, including AD. Indeed, these cells tend to 
localize around fibrillar amyloid plaques, suggesting that A deposition is a potent 
trigger of astroglial activation in the AD brain. 
1.6. Alzheimer’s Disease 
1.6.1. History 
The first AD case was described in 1907. Since then, major developments and 
findings mark the history of AD research in the general context of amyloid 
associated disorders. The term “amyloid” was first introduced by Virchow in 1854 to 
describe the macroscopic abnormalities associated with clinical symptoms, which 
appeared to represent the amylaceous constituents of plants upon staining with 
iodine. Five years later, Friedreich and Kekule suggested that amyloid is a protein 
rather than starch according to the high nitrogen content. The plaques in the AD 
brain were first described in 1898; the aniline dye Congo red facilitated specific 
discrimination from non-amyloid plaques in 1922. In 1907, Alois Alzheimer’s lecture 
about the first case of the fatal progressive dementia including extracellular plaque 
and intraneuronal NFT pathology did not receive special attention, although as a 
psychiatrist he was a pioneer at this time by associating pathological changes with 
dementia symptoms. 
Alzheimer’s colleague, Kraepelin, finally gave the disease its official name in 1910. 
Amyloid fibrils from tissue were first visualized by electron microscopy in 1959. X 
ray diffraction studies of isolated fibrils in 1968 revealed the so-called cross  
structure as a common motif [131]. 
In the 1970s, the availability of amino acid analysis and protein sequencing tools 
revealed that each amyloidosis is linked to a specific protein [132]. 
In 1984, A was identified as the major component of plaques from AD and Down 
syndrome patients [133]. Tau had already been described in 1975 as an essential 
protein for microtubule assembly [134], but it was not until one year after the 
identification of A that it was identified as the NFT forming protein. The 
corresponding MAPT gene was cloned in 1988 [135], again one year after the 
amyloid-  protein precursor (APP) gene containing the A sequence was cloned 
from chromosome 21 [136].  
16 
 
 
1.6.2. Introduction to the pathology 
Alzheimer’s disease (AD) is a highly debilitating neurodegenerative disorder that 
afflicts million of people and has reached in our society an enormous impact. The 
number of patients increases every year and recent projections predict 65 millions 
of AD worldwide by 2030. 
AD is the most common form of dementia, accounting for 60-80% of all cases 
(2010 Alzheimer’s disease facts and figures, 2010) and affecting people aged 85 or 
older with an incidence of 25-50% [124].  
Dementia is caused by various diseases and conditions that result in damaged 
brain cells or connections between brain cells. When making a diagnosis of 
dementia, physicians commonly refer to the criteria given in the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [125]. To meet 
DSM-IV criteria for dementia, the following are required: symptoms must include 
decline in memory and decline in at least one of the following cognitive abilities: 
 Ability to generate coherent speech or understand spoken or written language; 
 Ability to recognize or identify objects, assuming intact sensory function;  
 Ability to execute motor activities, assuming intact motor abilities, sensory 
function, and comprehension of the required task; 
 Ability to think abstractly, make sound judgments, and plan and carry out 
complex tasks. 
The decline in cognitive abilities must be severe enough to interfere with daily life. 
It is important for a physician to determine the cause of memory loss or other 
dementia-like symptoms. Some symptoms can be reversed if they are caused by 
treatable conditions such as depression, delirium, drug interaction, thyroid 
problems, excess use of alcohol, or certain vitamin deficiencies. When dementia is 
not caused by treatable conditions, a physician must conduct further assessments 
to identify the form of dementia that is causing symptoms. Different types of 
dementia are associated with distinct symptom patterns and distinguishing 
microscopic brain abnormalities. Although AD is the most common type of 
dementia, increasing evidence from long-term observational and autopsy studies 
indicates that many people with dementia have brain abnormalities associated with 
more than one type of dementia. 
AD was first identified more than 100 years ago, but research into its symptoms, 
causes, risk factors, and treatment has only gained momentum in the last 30 years. 
Although research has revealed a great deal about AD, with the exception of 
certain inherited forms of the disease, the cause or causes of AD remain unknown. 
As yet, neither a satisfying therapy nor a preventative cure is available. 
Furthermore, AD can only be precisely diagnosed post-mortem on a 
neuropathological basis, the so called Braak stages classify the progress of the 
disease [126]. 
AD is one of about 40 identified amyloidoses, whose main pathological hallmark is 
the aberrant deposition of amyloid fibrils in various tissues. Each of these diseases 
involves a specific protein and clinical profile, among them Parkinson’s disease, the 
prion diseases, diabetes type II, Huntington’s disease, and amyotrophic lateral 
sclerosis [127]. 
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1.6.3. Symptoms of Alzheimer’s disease 
AD can affect different people in different ways, but the most common symptom 
pattern begins with gradually worsening difficulty in remembering new information. 
This is because disruption of brain cell function usually begins in regions involved 
in forming new memories. As damage spreads, individuals experience other 
difficulties. The following are warning signs of AD: 
 Memory loss that disrupts daily life; 
 Challenges in planning or solving problems; 
 Difficulty completing familiar tasks at home, at work, or at leisure; 
 Confusion with time or place; 
 Trouble understanding visual images and spatial relationships; 
 New problems with words in speaking or writing; 
 Misplacing things and losing the ability to retrace steps; 
 Decreased or poor judgment; 
 Withdrawal from work or social activities; 
 Changes in mood and personality. 
Individuals progress from mild AD to moderate and severe disease at different 
rates. As the disease progresses the individual’s cognitive and functional abilities 
decline. 
In advanced AD, people need help with basic activities of daily living (ADLs), 
including bathing, dressing, using the bathroom, and eating. Those in the final 
stages of the disease lose their ability to communicate, fail to recognize loved 
ones, and become bed-bound and reliant on around-the-clock care. The inability in 
late-stage AD to move around can make a person more vulnerable to infections, 
including pneumonia. AD is ultimately fatal, and AD-related pneumonia is often the 
cause. Although families generally prefer to keep the person with AD at home as 
long as possible, most people with the disease eventually move into a nursing 
home or another residence where around-the-clock professional care is available 
[128]. 
1.6.4. Diagnosis of Alzheimer’s disease 
In 2011, the National Institute on Aging (NIA) and the Alzheimer’s Association 
recommended new diagnostic criteria and guidelines for AD. The new criteria and 
guidelines update, refine, and broaden guidelines published in 1984 by the 
Alzheimer’s Association and the National Institute of Neurological Disorders and 
Stroke. The new criteria and guidelines result from work that began in 2009, when 
more than 40 AD researchers and clinicians from around the globe began an in-
depth review of the 1984 criteria to decide how they might be improved by 
incorporating scientific advances from the past 3 decades.  
It is important to note that these are recommended criteria and guidelines. More 
research is needed, especially biomarker research, before the new criteria and 
guidelines can be used in clinical settings, such as in a doctor’s office. 
The new criteria differ from the original one, based chiefly on a doctor’s clinical 
judgment about the cause of a patient’s symptoms, taking into account reports from 
the patient, family members, and friend, results of cognitive testing and general 
neurological assessment, in two main aspects: 
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 Identification of three stages of AD with the first occurring before symptoms 
such as memory loss develop and before the affection of one’s abilities to carry out 
everyday activities; 
 Inclusion of biomarker tests such as levels of certain proteins in fluids (e.g. 
levels of tau and amyloid- in the cerebrospinal fluid and blood). 
The three stages of AD identified in the new criteria and guidelines are preclinical 
AD, mild cognitive impairment (MCI) due to AD, and dementia due to AD. These 
stages are different from the stages now used to describe AD, i.e. mild/early stage, 
moderate/mid stage, or severe/late stage. The new criteria propose that AD begins 
before the mild/early stage and that new technologies have the potential to identify 
AD-related brain changes that occur before mild/early stage disease. When these 
very early changes in the brain are identified, an individual diagnosed using the 
new criteria would be said to have preclinical AD or MCI due to AD. The third stage 
of the new criteria, dementia due to AD, encompasses all stages of AD as 
described today, from mild/early stage to severe/late stage. 
In the preclinical AD stage individuals have measurable changes in the brain, 
cerebrospinal fluid, and/or blood biomarkers that indicate the earliest signs of 
disease even if they have not yet developed symptoms such as memory loss. This 
preclinical or presymptomatic stage reflects current thinking that AD begins 
creating changes in the brain as many as 20 years before symptoms occur. 
Although the new criteria and guidelines identify preclinical disease as a stage of 
AD, they do not establish diagnostic criteria that doctors can use now. Rather, they 
state that additional biomarker research is needed before this stage of AD can be 
diagnosed. 
Individuals with MCI have mild, but measurable, changes in thinking abilities that 
are noticeable to the person affected and to family members and friends, but that 
do not affect the individual’s ability to carry out everyday activities. Studies indicate 
that as many as 10% to 20% of people aged 65 years have MCI. It is estimated 
that as many as 15% of people whose MCI symptoms cause them enough concern 
to contact their doctor’s office for an examination go on to develop dementia each 
year. From this estimate, nearly half of all people who have visited a doctor about 
MCI symptoms will develop dementia in 3 or 4 years [129]. This estimate is higher 
than for individuals, whose MCI is identified through community sampling (and not 
as a result of a visit to a doctor because of cognitive concerns). For these 
individuals, the rate of progression may reach 10% per year [130]. Further 
cognitive decline is more likely among individuals whose MCI involves memory 
problems than in those whose MCI does not involve memory problems. 
Over 1 year, most individuals with MCI who are identified through community 
sampling remain cognitively stable. Some, primarily those without memory 
problems, experience an improvement in cognition or revert to normal cognitive 
status. It is unclear why some people with MCI develop dementia and others do 
not. When an individual with MCI goes on to develop dementia, many scientists 
believe the MCI is actually an early stage of the particular form of dementia, rather 
than a separate condition. 
The new criteria and guidelines recommend biomarker testing for people with MCI 
to learn whether they have brain changes that put them at high risk of developing 
AD or other dementias. If it can be shown that changes in the brain, cerebrospinal 
fluid, and/or blood are caused by physiological processes associated with AD the 
new criteria and guidelines recommend a diagnosis of MCI due to AD. Before 
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doctors can make such a diagnosis, however, researchers must prove that the 
biomarker tests accurately indicate risk. 
Dementia due to AD is characterized by memory, thinking, and behavioural 
symptoms that impair a person’s ability to function in daily life and that are caused 
by AD-related processes. 
Current medical guidelines do not recommend that primary care physicians 
perform routine assessment for cognitive impairment or dementia in their patients, 
unless a patient exhibits obvious signs or symptoms of cognitive impairment.  
1.6.5. Etiology of Alzheimer’s disease 
The etiology of Alzheimer’s disease (AD), a condition characterized by progressive 
dementia with gradual loss of cognitive function, is still unresolved. During several 
decades, most research advances in Alzheimer’s disease were concentrated on 
the activity of neuronal cells. However in the past few years an increase set of 
evidence has converged on the major role of glial cells and alterations in their 
function, in the pathway toward neurodegeneration. There is growing evidence that 
indicate an involvement of the immune system and neuroinflammatory processes 
such as an increase of proinflammatory cytokines and activation of microglia and 
changes or defects in immune response in the blood of these subjects.  
Inflammation is a key component of an innate immune response. Innate immunity 
is a highly conserved system that protects the host from infectious and injury in a 
relative non-specific manner. It provides the first line of defence by recognizing 
pathogen-associated microbial patterns and inducing key co-stimulatory molecules 
and cytokines, which activate the mechanisms of the adaptive immunity. A 
multitude of factors are implicated in the response such as cytokines, the 
complement system, acute phase reactants and various cellular elements. While 
this system is an effective and potent response to acute challenges, it is imperative 
that it be tightly regulated over the longer term. Dysregulation and chronic 
activation can have detrimental effects on the host.  
The cause of AD is not clear, but ongoing research has identified a number of 
commonly accepted risk factors including genetic, biological and environmental 
factors. 
1.6.5.1. Genetic 
Aging is the most important known non-genetic risk factor for late-onset AD. 
Potential environmental risk factors include head injury, low educational levels, 
hyperlipidemia, hypertension, homocysteinemia, diabetes mellitus, and obesity 
[137-140]. However several of these associations remain controversial. 
Combination of one or more of these environmental risk factors with Apolipoprotein 
E4 (APOE4) may further increase the risk for late-onset AD and age-reated decline 
[141].  
AD cases can be divided into two main subtypes based on the age of onset: the 
(sporadic) late-onset AD (LOAD), characterized by disease manifestation at ages 
above 65 years, and early-onset (familial) AD (EOFAD), which occurs from 30 
years to 65 years. The early-onset familial forms of AD have an autosomal 
dominant inheritance linked to 3 genes: amyloid precursor protein (APP), 
presenilin-1 (PS-1), and presenilin-2 (PS-2), whereas the most common sporadic 
form of AD, which occurs after the age of 60, has thus far been consistently, across 
numerous studies, associated with only one gene, the APOE gene. 
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Mutations in three genes, APP, PS-1 and PS-2, cause early onset (<60 years) 
autosomal dominant AD [142], which probably accounts for less than 1% of AD 
cases [143]. The mutations affect APP processing, leading to altered production of 
different A peptides and, thus, their relative ratios. Down’s syndrome patient 
carrying an extra copy of chromosome 21, on which APP gene resides, develop 
early-onset dementia with pathological hallmarks of AD in their brains [144] 
consistent with the idea that over-expression of APP cause early-onset AD. In 
strong support to this idea, duplication of the APP gene alone leads to early-onset 
AD [145]. Moreover increased APP gene expression caused by genetic variations 
in the promoter sequence may be a risk factor for late-onset AD, with levels of APP 
expression correlating inversely with age of disease onset. 
While EOFAD is caused by rare and highly penetrant mutations in three genes the 
genetics of LOAD in more complex. Increasing age is the major risk factor for 
LOAD. In addition, APOE gene on chromosome 19 has been demonstrated to 
represent a major genetic risk factor.   
In 2003, the first A vaccination trial was eventually performed [147]. However, due 
to the occurrence of meningoencephalitis in some of AD patients, this initial trial 
had to be suspended. 
Apolipoprotein E4 (APOE4) has been genetically linked to late-onset (>60 years) 
familial and sporadic AD, which accounts for most AD cases, and has a gene-dose 
effect on increasing the risk and lowering the age of onset of the disease [148]. All 
well-conducted genome-wide association studies on late-onset AD from different 
populations around the world identified APOE4 as the top late-onset AD gene with 
extremely high confidence [142]. The lifetime risk estimate of developing AD for 
individuals with two copies of the APOE4 allele (~2% of the population) is the 
~60% by the age of 85, and for those with one copy of the APOE4 allele (~25% of 
the population) ~30%.  In comparison, the lifetime risk of AD for those with two 
copies of APOE3 allele is ~10% by the age of 85 years. Thus, APOE4 should be 
considered a major gene, with semidominant inheritance, for late-onset of AD 
[149]. 
Genome-wide association studies also identified other genes that modulate the risk 
of late-onset of AD, including CLU, CR1, PICALM, BIN1, SORL1, GAB2, ABCA7, 
MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and HLA-DRB1/5 [142]. However, the 
relative contribution of these genes to AD is modest as compared to apoE4. 
1.6.5.2. Epigenetic 
Epigenetics refers to modifications in gene expression that are influenced by DNA 
methylation and/or chromatin structure, RNA editing, and RNA interference without 
any changes in DNA sequences [150]. 
Epigenetic mechanisms may play a role in AD pathogenesis [151]. Studies on post-
mortem brain samples and peripheral leukocytes, as well as transgenic animal 
models, have shown that aging and AD are associated with epigenetic 
dysregulation at various levels, including abnormal DNA methylation and histone 
modifications. Although it is unclear whether the epigenetic changes observed in 
AD represent a cause or a consequence of the disease, twin studies support the 
notion that epigenetic mechanisms modulate AD risk [152]. 
1.6.5.3. The amyloid hypothesis 
The major pathological hallmarks in the brain of AD patients, in addition to nerve 
and synapse loss, are y the accumulation of amyloid- peptide into amyloid 
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plaques in the extracellular brain parenchyma and the formation of neurofibrillary 
tangles (NFT) inside neurons, as a result of the abnormal phosphorylation of the 
microtubules-associated tau- protein. Although tau is normally considered an 
intracellular protein, tau aggregates, named “ghost tangles”, are observed in the 
extracellular space [153] and tau peptide is readily detected in the cerebrospinal 
fluid of patients [154]. 
These lesions occur in brain regions involved in learning and memory, i.e. the 
hippocampus, the amygdala, and in the association cortices of the frontal, temporal 
and parietal lobes. Further A accumulation is observed in the small blood vessels 
of the meninges and cerebral cortex, also termed cerebral amyloid angiopathy 
[155].  
 
The amyloid hypothesis, formulated in the early 1990s [156,157], is based on the 
observation that A peptides accumulate into senile plaques; these lesions occur in 
brain regions involved in learning and memory, i.e. the hippocampus, the amigdala, 
and in the association cortices of the frontal, temporal and parietal lobes. Further 
the accumulation of A is observed in the small blood vessels of meninges and 
cerebral cortex, also termed cerebral amyloid angiopathy. Such accumulation is 
held responsible for neurodegeneration [158].  
Post-mortem examination of the brain of AD patients typically reveals a loss of 
synapses, and damage to neuritis associated with the plaques, which suggests 
that Aβ damages synapses and neurites. AD brains also exhibit a number of 
pathologic abnormalities including a loss of synapses, reactive gliosis, microglial 
activation, and neuroinflammation [159].  
A is generated as a normal product of the metabolism of the amyloid- protein 
precursor (APP), which is thought to be involved in neuronal growth, survival and 
post-injury repair [160]. Mature A PP is metabolized by two competing pathways: 
the -secretase pathway that generates sAPP and C83 and the -secretase 
pathway that generates sAPP  and C99. C99 is a substrare for -secretase 
generating A [161,162]. In the brain, A is produced mainly in various cellular 
compartments of neurons, but has also been detected in glial cells and astrocytes 
[163]. In vivo, A variants with lengths of 38-43 amino acids, differing in their C-
terminus, are produced due to differential cleavage of APP by secretase, following 
a mechanism termed regulated intramembrane proteolysis [164]. The most 
abundant variants are A1-40 and the more amyloidogenic A1-42, with an 
approximate ratio of 10:1. 
APP is ubiquitously expressed, and cells possess the enzymatic machinery 
required not only to produce it but also to degrade it, suggesting that the production 
of A from APP may serve a normal biological role. A PP is found mainly at the 
plasma membrane, but also in the trans-Golgi network, the endoplasmic reticulum, 
and at endosomal, lysosomal and mithocondrial membranes [165]. Different 
isoforms of A PP with lengths of 695-770 amino acid residues exist. The 
physiological function of A PP and its metabolic products are subject to intensive 
research. A PP knockout mice are viable but have been shown to display 
synaptic, learning and memory deficits. The number of functional synapses 
generally seems to be modulated by A PP in a dose-dependent manner. A PP 
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has been shown to be important for the regulation of neuronal survival, neurite 
outgrowth, synaptic plasticity and cell adhesion [166]. 
Amyloidogenic processing of A PP involves sequential cleavage by -secretase 
(also termed BACE1) and -secretase. Upon -secretase cleavage, the 
extracellular sAPP segment is released and the remaining C terminal C99 
fragment can be further processed by -secretase, producing A and AICD, or by 
caspases to release the neurotoxic peptide C31 [167]. AICD can translocate to the 
nucleus, where it regulates gene expression and potentially induces production of 
apoptotic proteins  [168]. Although a pathogenic role for A is generally accepted, 
the mechanisms remain poorly understood. 
Central to A hypothesis of AD is that disease progression is the result of an 
increase A burden in affected areas of the brain. Equally important to the total A 
load however is the aggregation state in which A is present. Initially produced as a 
soluble 4 kDa peptide, the amyloidogenic A readily interacts with other A 
molecules to progressively form a wide range of oligomers and soluble aggregates. 
Continued amyloidogenesis gives rise to the high molecular weight insoluble A 
fibrils that are present within amyloid deposits of the AD brain.  Amyloidogenesis is 
common to several proteins associated with degenerative disease, indicating that 
the mechanisms of degeneration may share some commonality with the respect to 
the proteins’ amyloidogenic properties [169]. 
A have also been shown to activate microglia and induce the production of 
inflammatory mediators such as NO, ROS, TNF-, Interleukins (IL-1, IL-6, IL-18), 
and prostaglandins (e.g., Prostaglandin E2 [PGE2]), that promote neuronal death 
[170]. These lines of evidence suggest that A accumulation directly contributes to 
neuronal damage and/or indirectly contribute to activation of inflammatory systems, 
leading to progression of AD. 
Significant amyloid deposition is a characteristic feature of all patients with 
Alzheimer’s disease; however, it is also present in many normal adults and in Mild 
Cognitive Impairment at a level higher than normal older adults and it is a strong 
predictive factor in conversion to AD [171]. Until the development of the amyloid-
sensitive ligands, there have been a variety of other techniques used to measure 
amyloid plaque accumulation, including methods that indirectly estimated levels of 
brain amyloid plaques from Alevels in plasma or cerebral spinal fluid (CSF). 
Postmortem studies, previously the only method examining Ahave found that 25-
30% of individuals with no clinical symptoms of dementia have levels of Aequal to 
the diagnostic level for AD [171]. In addition to measuring Alevels in the CSF, 
more recently Adeposits have become measureable using PET and radiotracer 
ligands that bind to the aggregated fibrillar form of A. The three most common 
ligands in use to image Adeposition with PET are the 11C-labeled PET tracer 6-
OH-BTA alzo known as Pittsburgh compound B or PIB [172], the 18F-labeled 
tracer FDDNP [173] and 18Florbetapir, also known as 18F-AV-45 [174]. While 
none of these compounds are FDA approved for clinical use, these amyloid 
imaging agents have been received with great interest in the research community 
and are in use in a number of clinical trials. The FDA has already approved the use 
of all three compounds as biomarkers to test the mechanisms of several putative 
amyloid lowering drugs [175]. 
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Less is known about the role of A in normal aging compared to the literature 
examining memory impairment or dementia. However, a few studies have 
measured amyloid deposition with respect to normal aging and the findings indicate 
the presence of deposits in frontal, cingulate, and parietal areas, with primary 
sensory/visual areas relatively protected from amyloid deposition. Studies with 
normal aging adult samples consistently report that approximately 20 to 30% of 
healthy older controls show significant amyloid deposition [176]. 
 
This finding led to many questions. One is whether cognitively normal subjects with 
elevated amyloid, as measured by PIB, display any subtle cognitive changes 
compared to their amyloid-negative counterparts. Thus far, the data have been 
mixed. Results from different studies are controversial. A couple of studies did not 
detect significant cognitive differences between healthy controls with and without 
increased levels of PIB binding [177,178]. However, Pike and colleagues reported 
that PIB uptake correlated with episodic memory performance [179]. Given the 
relatively small numbers of subjects in these studies and the potential for individual 
variability in cognitive performance, it is perhaps not surprising that these results 
have been somewhat inconsistent. Interestingly, in another study PIB PET scans 
were performed in a group of healthy elderly individuals who had been followed 
with psychometric testing for up to 10 years prior to the study [180]. This group was 
then divided into subjects who displayed some degree of cognitive decline over 
that period versus those who did not. Overall, the decliners were much more likely 
to display elevated PIB uptake, which suggests that the term “asymptomatic” may 
be relative. Along these lines, a recent report found evidence of cortical thinning in 
cognitively normal elderly with elevated PIB binding supporting the notion that 
despite being classified as normal, these individuals are already beginning to 
display neurodegenerative brain changes [181]. The existing evidence seems to 
suggest that amyloid is a critical initiating event in a cascade of events that 
ultimately leads to cognitive decline. Because amyloid deposition is putatively the 
first event in this negative cascade, many normal old adults harbor amyloid burden 
but behave within normal cognitive limits [182]. 
 
1.6.5.4. Tau hypothesis 
Another explanation, the tau hypothesis, is supported by the observation that tau 
hyperphosphorylation constitute a common feature explaining the alteration of the 
signalling pathways seen in degenerating neurons [183]. Neuroinflammatory 
processes and the activation of the immune system are present in AD; these 
processes are related to amyloid- containing plaques, [184,185] and are 
characterized as an increase of proinflammatory cytokines and as the activation of 
microglia in the AD brain [170].  
The tau protein was initially identified from isolated brain microtubules as a 
microtubule-associated protein (MAP). Subsequent in vitro analysis and studies in 
cultured cells then suggest that the tau protein facilitates assembly and stabilization 
of microtubule polymers. It has been suggested that alterations in the amount or 
conformation of tau, as well as other modifications to this protein, could have 
pathological effects. These modifications provoke disorders known as tauopathies 
[186], of which Alzheimer’s disease is the most prevalent. Tauopathies are 
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neurodegenerative diseases in which neurodegeneration is associated with the 
presence of phosphorylated or/and aggregated tau. 
The development of tau pathology in AD correlates with the neurodegeneration 
found during the progression of the disease [187], which also correlates with the 
appearance of phosphorylated tau [188]. In addition, an inverse relationship has 
been found in damaged regions between the number of extracellular NFT ghost 
tangles and the number of surviving cells [189]. This observation suggests that 
neurons containing NFT could degenerate and release their intracellular NFT into 
the extracellular environment [153], which may be toxic for the surrounding 
neurons [190]. 
An excess of tau protein could inhibit the trafficking of vesicles and organelles in 
neurons [191]. As several data concerning the toxicity of phosphorylated tau 
suggest, phospho-tau can sequester some other brain MAPs, producing 
disorganization of microtubule network that might be toxic to a neuron [192,193].  
The addition of recombinant tau protein to cultured neuronal cells produces an 
increase in intracellular calcium that could lead to neuron degeneration. As 
indicated above it has been suggested that endogenous intracellular tau may be 
released to the extracellular space upon neuron degeneration, where it could be 
toxic to other neurons [153]. Although it has been postulated that the presence of 
tau in the extracellular space is due to neuron degeneration, the presence of 
extracellular tau could be due to other causes. For example it might be exocytosed 
by cells, as indicated for the prion protein [194]. Indeed, intraneuronal transfer of 
tau protein between neurons in situ has been recently described, suggesting that 
N-terminal region of tau is required for tau secretion [195]. 
The increase of intracellular calcium induced by tau is caused by its interaction with 
M1 and M3 muscarinic receptors expressed by neurons [196]. As a result of 
neuronal death, oligomeric forms and tau filaments are released to the extracellular 
environment, contributing to activation of microglial cells and stimulating the 
deleterious cycle leading to neurodegeneration and neuroinflammation.  
Neuroinflammation plays a fundamental role in the progression of Alzheimer’s 
disease and other tauopathies. It is well documented that extracellular aggregates 
of amyloid-, which senile plaques are consisted of, are considered responsible for 
initiating the non-immune mediated chronic inflammatory response manifested by 
activated microglia and astrocytes. Amyloid-deposits attract microglia and 
activated them to produce acute-phase proteins, complement compounds and 
chemokines. Activated microglia are also present around neurofibrillary tangles at 
early as well as later stages of tangle formation [197]. 
Further it has been demonstrated that microglia activation was also correlated with 
tau burden in other human tauopathies [198,199]. In a rat model of tauopathy it has 
been demonstrated that neurodegenerative lesions caused by human truncated 
tau promote inflammatory response manifested by upregulation of immune 
molecules (CD11a,b, CD18, CD4, CD45, and CD68) and morphological activation 
of microglia cells. In the transgenic rat brain neurofibrillary lesions and axonal 
degeneration were closely associated with the distribution of reactive microglia and 
macrophage, differently involved in the grey and white matter lesions: while 
activated microglia cells prevail in the grey matter lesions, macrophages were 
dominant in the white matter lesions. Activation of microglia is characterized by 
proliferation, migration to the site of injury, morphological characteristics, 
immunophenotypical (upregulation of innate immune cell surface receptors) and 
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functional changes (antigen-presenting cell capabilities). In parallel the innate 
immune brain response promotes activation of MHC class II positive blood-borne 
leukocytes and their influx into brain parenchyma [200]. 
The pathogenic role of intracellular pathological aggregates of tau protein, has not 
been completely clarified either. The abnormal hyperphosphorylation of tau, which 
can be generated by catalysis of several different combinations of protein kinases, 
also promotes its misfolding, decrease in turnover, and self-assembly into tangles 
of paired helical and straight filaments. 
Disruption of microtubules by the non-fibrillized abnormally hyperphosphorylated 
tau, as well as its aggregation as neurofibrillary tangles, probably impair the 
axoplasmic flow and results in loss of connectivity of the affected neurons. It is still 
not clear whether the hyperphosphorylation of tau is critical to neurotoxicity until 
now. It has been proposed that a time-limited hyperphosphorylation/ accumulation 
of tau may be neuroprotective but prolonged hyperphosphorylation/ accumulation 
of tau may be associated with neurodegeneration [201,202]. 
Recent data indicate that tau self-polymerization into pathological oligomers and 
filaments could be a major culprit for neurofibrillary degeneration [203]. Thus, a 
series of endogenous signals could activate the microglia. In particular signals like 
amyloid- oligomers, iron overload, oxidative stress molecules, and low-density 
lipoprotein, would activate microglia cells via RAGE receptor or TLR4; this would 
result in the induction of NFkappa-beta (NFkB) with a consequent release of pro-
inflammatory cytokines. An overexpression of these mediators may trigger 
signalling cascades in neurons, leading to the activation of various protein kinases 
and the inactivation of phosphatases such as PP1, with a resulting 
hyperphosphorylation and self-aggregation of tau protein into neurotoxic oligomeric 
species. 
1.6.6. Therapies 
There are four licensed pharmacological treatments for AD, which provide 
symptomatic benefit: three acetylcholine esterase inhibitors (donepezil, 
rivastigmine, galantamine), which are licensed for the treatment of people with 
mild-to-moderate AD and memantine, an NMDA receptor antagonist, which is 
licensed for the treatment of people with moderate-to-severe AD. The existing 
drugs do not specifically target the underlying pathology of AD. Instead, current 
treatments target cholinergic or glutamatergic function. 
Cholinergic function is compromised in AD [204] following early loss of basal 
forebrain cholinergic neurons. Treatments mainly focus on inhibition of 
acetylcholine esterase or modulation of muscarinic and nicotinic acetylcholine 
receptors. 
Treatment with acetylcholinesterase inhibitors results in a moderate improvement 
in cognition (1.5-2 points on the MMSE over 6-12 months), shortterm (3-6 months) 
improvement in global outcome and some additional short-term stabilization of 
overall cognitive function [205,206]. There is also more limited evidence of modest 
improvements in mood (particularly apathy) and social interaction [207].  
 
1.6.6.1. Targeting A 
The amyloid cascade hypothesis has been the basis of the majority of potential 
disease-modifying treatments for AD. Approaches to target amyloid are 
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characterized within three main strategies: treatments to reduce A (and/or A 1-
42) production, approaches to promote clearance of A and treatments to reduce 
A aggregation. 
The primary approach to treatments to reduce the production of A is through 
targeting the AP proteolytic process performed by secretases to alter the A 1- 40/ 
A 1-42 ratios. This has involved either inhibiting or modifying -, - and -
secretase to shift the process toward production of A1-40. Although - and -
secretase inhibition could be a promising way to achieve this, there are significant 
barriers to overcome. One of the main difficulties is to designe an inhibitor that will 
retain the ability to cross the blood brain barrier. In addition, both - and -
secretases are active against numerous substrates, which raise the risk of causing 
significant adverse effects with a non-specific inhibitor [208]. 
Techniques to promote removal of A from the brain have focused on 
immunization as a therapeutic strategy. Proposed mechanisms include targeting of 
either soluble or aggregated A through antibody binding, phagocytosis or direct 
extraction by plasma antibodies. 
Initial approaches based on immunization with A fragments performed extremely 
well in transgenic mouse models but showed less promise in humans [209]. The 
most promising of these, AN-1792 (QS-21) resulted in significant A -antibody 
titers in patients with mild-moderate AD in Phase II trials. Post-mortem analysis on 
long-term follow-up also confirmed that the therapy had resulted in significant 
reduction in A burden in the brain. However, there was no evidence of any clinical 
benefit and the trial was stopped due to patients developing aseptic 
meningoencephalitis, thought to have been induced by cytotoxic T-cell activation 
[210]. 
Immunization strategy has focused on two main techniques, either intravenous 
delivery of immunoglobulins (IVIg) from healthy donors or infusion of monoclonal or 
polyclonal anti- A antibodies. Monoclonal antibody therapies currently in trials 
include bapineuzumab (AAB-001), solanezumab (LY-2062430), PF-04360365, 
GSK-933776, R-1450 (RO-4909832) and MABT-5102A, of which bapineuzumab 
and solanezumab are now in Phase III RCTs. Solanezumab is designed to target 
soluble A, drawing on evidence that these species of A confer the highest 
toxicity. It has performed well in trials to date [211]. 
Current literature supports the hypothesis that small soluble A oligomers are 
responsible for neurotoxicity and synaptotoxicity in AD [164,212]. Drug 
development has, therefore, focused on identifying compounds to inhibit 
aggregation or to specifically target oligomeric forms of A. This raises similar 
challenges in toxicity and blood brain barrier penetration as are encountered with 
secretase inhibitors. However, all the trials were halted for treatment groups 
receiving high doses due to significant adverse effects. 
 
1.6.6.2. Anti-tau therapies  
Treatments to target tauopathy in AD have received far less attention than amyloid 
therapies, and only one treatment has been taken to Phase III trial. Immunotherapy 
Inhibition of glycogen synthase kinase (GSK) 3 has been hypothesized as a 
promising approach since GSK-3 is a key enzyme in tau phosphorylation. 
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However, a Phase III trial with the anticonvulsant sodium valproate showed no 
benefit and an increase in AD progression and mortality [213]. 
 
1.6.6.3. Additional approaches 
In an effort to improve neuronal function, a number of treatments have been 
proposed. This includes therapeutic approaches based on evidence for the role of 
trophic factors such as nerve growth factors (NGF). 
Several innovative approaches are also in development and evaluation, including 
delivery of genetic factors to boost NGF production via a viral vector (CERE 100) 
and techniques using cutting-edge nanotechnology, which have shown promise in 
animal models [214]. 
 
Additional approaches to AD treatment have also been explored as routes to 
prevent pathological processes although progress in these areas has been limited. 
These areas include mitochondrial dysfunction, trophic factor depletion, loss of 
synaptic plasticity, inflammation and hypertension [215]. 
Because there is plenty of evidence for oxidative damage, inflammation and 
mitochondrial impairments in AD [216,217], several attempts have been made to 
slow disease progression with antioxidants [218], anti-inflammatory drugs [219], or 
putative mitochondrial protectors. The rationale for these approaches is based on 
animal studies, epidemiological evidence and in some cases very preliminary 
studies in people with AD and/or other dementias. 
 
1.7. Neuroinflammation in AD 
Inflammation is a key component of an innate immune response. 
Innate immunity is a highly conserved system that protects the host from infectious 
and injury in a relatively non- specific manner. Sustained inflammation resulting in 
tissue pathology implies persistence of an inflammatory stimulus or a failure in 
normal resolution mechanisms. A persistent stimulus may result from 
environmental factors or the formation of endogenous factors (e.g. protein 
aggregates) that are perceived by the immune system as “stranger” or “danger” 
signals. Inflammatory responses reestabilished feed-forward loops may overwhelm 
normal resolution mechanisms. Although some inflammatory stimuli induce 
beneficial effects (e.g. phagocytosis of debris and apoptotic cells) and inflammation 
is linked to tissue repair processes, uncontrolled inflammation may result in 
production of neurotoxic factors that amplify underlying disease states. 
A multitude of factors are involved in the overall response such as cytokines, the 
component system, acute phase reactants and various cellular elements, which in 
concert mount a powerful action. Dysregulation and chronic activation can have 
detrimental effects for the host by extending focal damage into nearby healthy 
tissue, a process termed “bystander damage”. Controlling and reducing the 
damaging properties of inflammation have proven to be useful in the therapy of a 
number of peripheral disorders such as atherosclerosis and rheumatoid arthritis. 
Chronic inflammation has been implicated not only in diseases of the periphery, but 
also in the central nervous system in neurodegenerative disorders such as 
Alzheimer’s disease, Parkinson’s disease (PD) and amyotrophic lateral sclerosis 
(ALS). 
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Evidence of an inflammatory response in AD includes changes in microglia 
morphology, from ramified (resting) to ameboid (active), and astrogliosis, 
manifested by an increase in the number, size, and motility of astrocytes, 
surrounding and enveloping the A senile plaques [220,221]. 
Compared to those found in the non-demented brain, these microglia express 
higher levels of a number of cell surface proteins, including the major 
histocompatibility complex II cell surface glygcoprotein. In addition, a variety of 
other cell surface proteins are upregulated on activated microglia neighboring A 
plaques. Microglia surrounding plaques stain positive for activation markers and 
proinflammatory mediators, including MHC class II, COX-2, MCP-1, TNF-, IL-1, 
and IL-6 [170]. MCP-1 is known to induce chemotaxis of astrocytes around senile 
plaques [221]. In addition, elevated levels of chemokines and cytokines and their 
receptors, including, IL-1, CXCR2, CCR3, CCR5, and TGF- have been reported 
in post-mortem AD brains [222]. 
Microglia surrounding plaques have also been shown to proliferate, contributing to 
their accumulation at the plaque periphery [220,221]. Some aspects of the 
microglial inflammatory response represent positive influences with respect to AD 
pathogenesis, such as phagocytosis, which may participate in the removal of A 
from the brain. 
Inhibition of microglial activity protects the brain from inflammatory lesions [223]. 
Collateral injury is mediated by inflammatory factors that are either neurotoxic 
themselves or attract the migration of leucocytes into the affected area, which, in 
turn, propagate a detrimental inflammatory environment. In most organs 
inflammation leads to collateral injury, which is typically reversible, given the 
inherent regenerative capacity of that tissue. However, in the brain the stakes are 
higher. The consequence of collateral injury in the CNS is irreversible neuronal loss 
and atrophy due to two specific circumstances: first, the outstanding susceptibility 
of neurons to cell death mediated by molecules generated during the respiratory 
burst of an innate immune response [224,225] and second, regenerative failure of 
the brain as the combined consequence of molecular inhibitors of axonal growth 
[226,227] as well as limited repopulation by resident neuronal precursors [228]. 
Expression of inflammatory mediators has been demonstrated in affected brain 
regions [99]. Some pharmacological inhibitors and modulators of inflammation, 
such as nonsteroidal anti-inflammatory drugs (NSAIDs), have been shown to exert 
protective effects in several epidemological studies as well as in animal models of 
neurodegenerative disease [229,230].  
Age-related dysfunction of microglial cells can be a significant cause underlying 
age-related neurodegenerative diseases such as AD [231]. Microglia display 
several morphological changes, which are pronounced with aging. Senescent 
dystrophic microglial cells show decreased arborization and beading of their 
processes [232,233] and abnormal cytoplasmic structures [232,234]. Senescent 
like microglia colocalize with neurodegenerating neuronal cells and show functional 
deterioration, including a high incidence of clumping, particularly in white matter 
[235]. 
It is especially interesting that senescent dystrophic microglial cells precede the 
appearance of tau neuropathology [233]. Microglia also show progressive 
replicative senescence characterized by an increased microglial proliferation in 
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response to nerve injury [236] and inflammatory hyper responsiveness as a 
function of age [237]. 
 
The role of microglia in Alzheimer disease has not been solved. Microglia can be 
neuroprotective by phagocytosing amyloid-, but the activation of microglia and the 
secretion of neurotoxins may also cause neurodegeneration. Notably, in vitro 
studies using human cultured microglia have shown that aggregated amyloid-beta 
peptide could result in the activation of such microglia, inducing a proinflammatory 
status [238]. Activated microglia and reactive astrocytes localize in the proximity of 
fibrillar plaques, and initially, the phagocytic microglia engulfs and degrades 
amyloid-. Nevertheless, chronically activated microglia releases chemokines and 
a cascade of pro-inflammatory cytokines- notably IL-10, IL-6, TNF-. Microglia also 
expresses receptors for advanced glycation and products that bind amyloid-, 
thereby amplifying the generation of cytokines, glutamate, and nitric oxide. 
Importantly, the levels of pro-inflammatory cytokines are dependent on the 
magnitude of plaque burden in the AD brain [239] and it has been suggested that 
the inflammatory response facilitates the production and deposition of A 
[170,239]. 
In the past few years, it has become evident that the innate immune system and, in 
particular, pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) 
play a major role in infectious but also in non-infectious CNS diseases. Activation 
of TLRs expressed in microglia leads to oligodendrocyte and neuronal injury 
[240,241].  
There is clear evidence that TLR4 can trigger amyloid-beta induced activation of 
murine microglia and human monocytes [242]. Interestingly, TLR2 was also shown 
to be an important signalling receptor in neuroinflammation, especially in brain 
injury [243]. 
TLRs are demonstrated to mediate microglial activation and clearance of A from 
the brain [242,244]. In addition to CD14 and TLRs functioning in microglial 
activation, CD14 functions in the recognition and clearance of A- damaged 
neurons [245]. Thus, the innate immune system is truly a double-edged sword. It 
has been proposed that at low A concentrations corresponding to those observed 
in the brain of early/middle stage AD, CD14 and TLRs may activate microglia 
promoting phagocytic clearance of A, whereas at higher A concentrations 
corresponding to those at late stage AD, microglial activation through CD14 and 
the TLRs results in production of neurotoxins as well, thereby damaging 
surrounding neurons [244] and killing these damaged neurons. The recognition of 
the involvement of TLRs and their co-receptors in AD pathogenesis suggests that 
they may be an appropriate target for therapeutic intervention within the disease. 
Peripheral blood macrophages from AD patients were also found to be less 
effective in phagocyting amyloid-beta, and monocytes were impaired when 
differentiating into macrophages [246].  
The mechanism of microglial accumulation into normal or Alzheimer disease is not 
established. In normal adult brain a limited number of mononuclear phagocytes are 
continuously recruited into the brain where they may differentiate into parenchymal 
microglia.  
The role of chemokines and their receptors in the recruitment and retention of 
microglia in normal and Alzheimer disease brains is not known either. Mononuclear 
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phagocytes (CD16-), including microglia, express several chemokine receptors 
such as CCR2. Monocyte chemotactic protein-1 (MCP-1), the main CCR2 
chemokine ligand, is upregulated in brains of AD patients [247]. CCR2 mediates 
the accumulation of mononuclear phagocytes from bone marrow at sites of 
inflammation. CCR2 deficiency accelerates early disease progression and 
markedly impairs microglial accumulation in a transgenic model of Alzheimer 
disease [248]. 
From a mouse model has emerged that resident monocytes, blood monocytes and 
NK cells (CD16
+ 
in humans) express high levels of CX3CR1 which, upon 
interaction with CX3CL1 facilitates extravasation into non-inflamed tissues where 
these cells give rise to specialized cell types. These finding suggest that CD16
+
 
and CD16- monocytes are recruited into different anatomic sites under constitutive 
or inflammatory conditions and play distinct roles in immunity and disease 
pathogenesis. 
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2. AIM OF THE STUDY 
It is now clear that immune responses do occur in the CNS, can be driven by 
endogenous (glial) and/or exogenous (peripheral leukocytes) sources, and can 
play either a protective or a pathological role [249]. Peripheral 
monocyte/macrophage recruitment in CNS could restrict amyloid- beta plaques 
[250]. In this context is noteworthy to underline that activated endothelium and 
microglia can present amyloid-beta peptides to T cells, thus inducing an adaptive 
immune response.  
Whether the arrival of T-cells is beneficial or detrimental is not understood. 
However, certainly in the case of massive T-cell response (for instance in amyloid-
beta vaccine-related meningoencephalitis), the effects seem to overwhelmingly 
negative. T cells are activated and display memory phenotype in AD patients; 
these cells can be detected both in the periphery and as infiltrates in the brain [96]. 
Upon antigen stimulation, peripheral CD4
+
 naive T cells can differentiate into 
different subsets characterized by different signalling pathways of activation, 
transcription factors expression, cytokine production profiles and effectors 
functions. Th-1 cells secrete IL-2, IL-12, IFN-, and TNF-, promoting cellular 
immune responses against intracellular pathogens and viruses. Th-2 cells produce 
IL-4, IL-5, IL-6, IL-10 and IL-13 and mostly mediate protection against extracellular 
pathogens. Th-17 cells produce IL-17, TNF-, IL-21, and IL-22 and play a pivotal 
role in protection against extracellular pathogens and fungi, besides being involved 
in tissue inflammation or autoimmune disease. 
In this context immune-mediated tolerance could play an important role in AD-
associated neuroinflammation. One of the main way in which this process is 
modulated is the reciprocal balance between two molecules present on the surface 
of immune and non-immune cells: programmed death 1 (PD-1)/ programmed death 
1 ligand-1 (PD-L1). PD-1 is expressed on activated T-cells and can bind PD-L1, 
which is constitutively present on monocytes and can be induced on activated T 
cells [70]. This interaction results in the up-regulation of IL-10 production, reduction 
of T cells proliferation [67,77,64], and induction of apoptosis of antigen-specific 
cells. This pathway thus plays a pivotal role in tolerizing and destroying self 
antigens-specific cells, therefore preventing autoimmunity. 
A major unresolved question is whether inhibition of these responses will be safe 
and effective means of reversing and slowing the course of disease. To effectively 
address this question it will be necessary to learn more about how inflammatory 
responses are induced within the central nervous system and the mechanisms by 
which these responses ultimately contribute to the pathology. 
Objectives of this study are to assess the role of innate and adaptive immune 
responses in the onset and the progression of neuroinflammation-associated AD. 
In particular, we plan to analyze a number of potentially interesting biomarkers to 
verify their possible role as prognostic markers and as markers predicting the long-
term disease evolution and as new tools in therapeutic strategies. To realize this 
goal we will analyze A-stimulated peripheral blood mononuclear cells (PBMC) 
isolated from blood samples of AD and MCI patients; results will be compared to 
those obtained in age, sex matched control group (HC) without dementia. 
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3. MATERIAL AND METHODS 
3.1. Flow cytometry principles 
Flow cytometry is a technique for making rapid measurements on particles or cells 
(including nuclei, microorganisms, chromosome preparations, and latex beads) as 
they flow in a fluid stream one by one. Physical properties, such as size 
(represented by forward angle light scatter) and internal complexity (represented by 
right-angle scatter) can resolve certain cell populations. Flow cytometry is 
employed in cell counting, sorting, biomarker detection and protein engineering as 
it allows simultaneous multiparametric analysis of the physical and/or chemical 
characteristics of up to thousands of particles per second. 
A beam of light (usually laser light) of a single wavelenght is directed onto a 
hydrodynamically-focused stream of liquid. A number of detectors are aimed at the 
point where the stream passes through the light beam: one in line with the light 
beam (Forward Scatter or FSC) and several perpendicular to it (Side Scatter or 
SSC) and one or more fluorescence detectors. Each suspended particle from 0.2 
to 150 micrometers passing through the beam scatters the ray, and fluorescent 
chemicals found in the particle or attached to the particle may be excited into 
emitting light at a longer wavelength than the light source. Scattered and emitted 
light from cells and particles are converted to electrical pulses by optical detectors. 
This combination of scattered and fluorescent light is picked up by the detectors, 
and, by analysing fluctuations in brightness at each detector (one for each 
fluorescent emission peak), it is then possible to derive various types of information 
about the physical and chemical structure of each individual particle. 
FSC correlates with the cell volume and SSC depends on the inner complexity of 
the particle (i.e., shape of the nucelus, the amount and type of cytoplasmic 
granules or the membrane roughness). This is because the light is scattered off of 
the internal components of the cell. A flow cytometer has five main components:  
a flow cell - liquid stream (sheath fluid), which carries and aligns the cells so that 
they pass single file through the light beam for sensing; 
 a measuring system - commonly used are measurement of impedance (or 
conductivity) and optical systems - lamps (mercury, xenon);  
 high-power water-cooled lasers (argon, krypton, dye laser); low-power air-
cooled lasers (argon-488 nm, red-HeNe-633 nm, green-HeNe, HeCd-UV); diode 
lasers (blue, green, red, violet) resulting in light signals; 
 a detector and Analogue-to-Digital Conversion (ADC) system - which generates 
FSC and SSC as well as fluorescence signals from light into electrical signals that 
can be processed by a computer an amplification system, linear or logarithim; 
 a computer for analysis of the signals. 
A wide range of fluorophores can be used as labels in flow cytometry. 
Fluorophores, or simply "fluors", are typically attached to an antibody that 
recognises a target feature on or in the cell; they may also be attached to a 
chemical entity with affinity for the cell membrane or another cellular structure. 
Each fluorophore has a characteristic peak excitation and emission wavelength, 
and the emission spectra often overlap. Consequently, the combination of labels 
which can be used depends on the wavelength of the lamp(s) or laser(s) used to 
excite the fluorochromes and on the detectors available.  
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The most commonly used fluorophores are fluorescein (FITC), phycoerythrin (PE), 
Phycoerythrin-Cyanin-5 (PC5), Phycoerythrin-Cyanin-7 (PC7), energy coupled dye 
(ECD), propidium iodide (PI), ethidium bromide (EtBr), allophycocyanin (APC). 
Fluorescence measurements taken at different wavelengths can provide 
quantitative and qualitative data about fluorochrome-labeled cell surface receptors 
or intracellular molecules such as DNA and cytokines.  
Flow cytometers use separate fluorescence (FL-) channels to detect light emitted. 
The number of detectors will vary according to the machine and its manufacturer. 
Detectors are either silicon photodiodes or photomultiplier tubes (PMTs). Silicon 
photodiodes are usually used to measure forward scatter when the signal is strong. 
PMTs are more sensitive instruments and are ideal for scatter and fluorescence 
readings. The specificity of detection is controlled by optical filters, which block 
certain wavelengths while transmitting (passing) others. There are three major filter 
types. ‘Long pass’ filters allow through light above a cut-off wavelength, ‘short pass’ 
permit light below a cut-off wavelength and ‘band pass’ transmit light within a 
specified narrow range of wavelengths (termed a band width).  
All these filters block light by absorption. 
When a filter is placed at a 45
o
 angle to the oncoming light it becomes a dichroic 
filter/mirror. As the name suggests, this type of filter performs two functions, first, to 
pass specified wavelengths in the forward direction and, second, to deflect blocked 
light at a 90
o 
angle. To detect multiple signals simultaneously, the precise choice 
and order of optical filters will be an important consideration. 
3.2. Cell sorting 
Fluorescence-activated cell sorting (FACS) is a specialized type of flow cytometry. 
It provides a method for separating physically (sort) a heterogeneous mixture of 
biological cells into two or more containers, one cell at a time, based upon the 
specific light scattering and fluorescent characteristics of each cell. It provides fast, 
objective and quantitative recording of fluorescent signals from individual cells as 
well as physical separation of cells of particular interest.  
The cell suspension is entrained in the centre of a narrow, rapidly flowing stream of 
liquid. The flow is arranged so that there is a large separation between cells 
relative to their diameter. The majority of instruments use electrostatic deflection of 
droplets for the sorting of cells. A vibrating mechanism causes the stream of cells 
to break into individual droplets. The system is adjusted so that there is a low 
probability of more than one cell per droplet. Just before the stream breaks into 
droplets, the flow passes through a fluorescence measuring station where the 
fluorescent character of interest of each cell is measured. An electrical charging 
ring is placed just at the point where the stream breaks into droplets. A charge is 
placed on the ring based on the immediately prior fluorescence intensity 
measurement, and the opposite charge is trapped on the droplet as it breaks from 
the stream. The charged droplets then fall through an electrostatic deflection 
system that diverts droplets into containers based upon their charge. In some 
systems, the charge is applied directly to the stream, and the droplet breaking off 
retains charge of the same sign as the stream. The stream is then returned to 
neutral after the droplet breaks off. 
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3.3. Patients and controls 
One-hundred-and-twelve elderly Italian individuals were enrolled in the study: 38 
patients had a diagnosis of AD, 34 patients had a diagnosis of MCI, 40 individuals 
were healthy. The clinical diagnosis of AD was performed by the Neurology 
Department of Don Gnocchi Foundation in Milan, Italy, according to NINCDS-
ADRDA work group criteria [251] and DMS IV-R [125]. The mean age of AD 
patients (17 males and 21 females) was 77.14 years (age range 59-81 years). All 
patients underwent complete medical and neurological evaluation, laboratory 
analysis, CT scan or MRI, and other investigations, when necessary (e.g. EEG, 
SPET scan, CSF examination, etc.), to exclude reversible causes of dementia. 
Neuropsychological evaluation and psychometric assessment was performed with 
a Neuropsychological Battery including Mini-Mental State Examination (MMSE) 
[252], Digit Span Forward and Backward, Logical Memory and Paired Associated 
Words Tests, Token Test, Supra Span Corsi Block Tapping Test, Verbal Fluency 
Tasks, Raven Colored Matrices, the Rey Complex Figure, Clinical Dementia Rating 
Scale (CDR) [253] and the Hachinski Ischemic Scale.  
Thirty-five patients were late and three early AD onsets; all cases were sporadic. 
MMSE and CDR scales were used to assess the severity of dementia.  
AD patients were divided into three subgroups:  
 Mild dementia (MMSE= 20-28; CDR= 0,5-1; N= 17; mean age: 74.22 + 1.8 
years; mean MMSE values: 23.4 + 1.5); 
 Moderate dementia (MMSE= 15-19; CDR= 2; N= 13; mean age: 78.51 + 1.2 
years; mean MMSE values: 17.7 + 1.3);  
 Severe dementia (MMSE= 0-14; CDR= 3; N= 8; mean age: 79.2 + 1.4 years; 
mean MMSE values: 7.4 + 1.3).  
Blood count, urine analysis, blood chemistry screen, serum folate, B12 levels, and 
thyroid functions tests were normal in all patients and none of them suffered from 
malnutrition or vitamin deficiency syndromes. 
MCI patients were selected among subjects who came to our Memory Disorders 
Outpatients Service for the diagnostic evaluation of memory complaints without 
difficulties in daily activities. The diagnosis of MCI was based on the unanimously 
adopted criteria proposed by Petersen [129] as follows:  
 Reported cognitive decline,  
 Impaired cognitive function,  
 Eessentially normal functional activities, and  
 Exclusion of dementia.  
The mean age of MCI patients (18 males and 16 females) was 75.86 years (age 
range 59-83).   
All subjects received a thorough clinical history, neurological examination, 
laboratory test, and brain MRI to exclude hydrocephalus, intracranial mass, 
infarcts, moderate to severe non-specific white matter disease and reversible 
causes of cognitive impairment. Patients with structural abnormalities that could 
impair cognitive function, other than cerebrovascular lesions, were excluded. No 
MCI patient received cholinesterase inhibitor or anticholinergic treatment. Every 
patient was followed up with annual brain MRI and routine laboratory tests, and re-
evaluated approximately every 6 months with neurological examination and a 
battery of neuropsychological tests and scales.  
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Forty healthy elderly subjects, age- and sex-matched with the patient (healthy 
controls; HC), were enrolled as well. These individuals were selected according to 
the SENIEUR protocol for immuno-gerontological studies of European 
Community’s Control Action Programme on Aging [254,255] and were either 
unrelated healthy spouses of AD and MCI patients or healthy volunteers. The 
cognitive status of HC was assessed by administration of MMSE (score for 
inclusion as normal control subjects  > 28). 
All individuals enrolled in the study, and their relatives when appropriate, provided 
written informed consent according to a protocol approved by a local ethics 
committee of the Don C. Gnocchi Foundation before admission to the study. 
3.4. Blood sample collection and cell separation 
Whole blood was collected by venopuncture in Vacutainer tubes containing 
ethylenediaminetetraacetic acid (EDTA) (Becton Dickinson & Co., Rutherford, NJ, 
USA). Peripheral blood mononuclear cells (PBMCs), consisting of T lymphocytes, 
B lymphocytes, monocytes and natural killer cells, were separated on lymphocyte 
separation medium (Fycoll-Hypaque, Organon Teknika Corp., Durham, NC, USA) 
and washed twice in PBS; viable leukocytes were determined using a Scepter
TM 
Handheld Automated Cell Counter (Millipore, MA, USA).  
3.5. CFDA-SE labeling  
PBMC resuspended at 10
7
 /ml in PBS were added to an equal volume of 5 M of 
5-6 carboxyfluorescein diacetate succimidyl ester (CFSE) (Molecular Probe, 
Eugene, OR) in PBS and mixed for 10 minutes at room temperature. This 
procedure has a labeling efficiency exceeding 99%, and cells remain labeled for at 
least 10 days during tissue culture [256]. CFSE reacts with secondary amino of 
intracellular proteins providing a uniform fluorescent label. Upon cell division a 
CFSE
high
 cell (high fluorescence intensity) will lose half of its CFSE fluorescence 
intensity (CFSE
low
) resulting in populations of daughter cells (proliferating cells), 
which can be visualized by flow cytometry. 
3.6. Stimulation of PBMC for FACS analysis 
10 x 10
6 
PBMC were cultured in 10ml of RPMI-1640 supplemented with 10% AB 
serum and stimulated with either non-immunogenic peptides [257] or with a pool of 
three different A peptides: 1-40, 1-16, and 1-35 (10 g/ml)(Sigma, St.Louis, MO, 
USA) at 37° C in a humidified 5% CO2 atmosphere for 24 hours. These fragments 
are largely present in cerebral deposits of A-protein in senile plaques, induce 
inflammatory mediators [251,258,170] and circulate in plasma and CSF [259,260]. 
For cytokine analyses, 10 g/ml Brefeldin A (Sigma-Aldrich)
 
was added to the cell 
cultures during the last 6 h of stimulation
 
to block protein secretion.  
3.7. Proliferation Assay  
CFSE-labeled cells were washed twice and resuspended at 3x10
6
 cells/ml in 
polystyrene tissue culture tubes containing 1 ml RPMI-1640 medium supplemented 
with 10% AB serum. Cells were then stimulated with either non-immunogenic 
peptides [257] or with a pool of three different fragments of amyloid- (A)-protein: 
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fragment 1-40, fragment 1-16 and fragment 1-35 (10g/ml)(Sigma, St.Louis, MO, 
USA) at 37° C in a humidified 5% CO2 atmosphere for 5 days.  
 
Cells were subsequently harvested and washed twice in PBS. Surface staining for 
CD3, CD4 and CD8 was performed for 30 minutes at 4°C, finally cells were 
washed in PBS and fixed in 1% paraformaldehyde. Proliferation in non-
immunogenic peptides- stimulated samples was considered to be the background 
value. The ∆ Proliferating Fraction (PF) was calculated by subtracting background 
proliferation from the antigen-specific proliferation. Stimulation indexes (SI) were 
calculated by dividing antigen-induced proliferation by background proliferation. 
Both a ∆ PF > 1% and an SI > 2.0 were required to classify a response as positive 
[261]. 
3.8. Cell purification  
CD4
+
 T cells were isolated using a negative CD4
+
 T cell isolation kit (EasySep, 
StemCell Technologies, Grenoble, France). CD4
+
 CD25
high
 (Treg) and 
CD4
+
CD25
neg
 (Tresp) cells were separated using the ALTRA EPICS cell sorter 
(Beckman-Coulter). Freshly isolated CD4
+
 T cells were stained for 40 min at 4° C 
with human CD25-specific PC-5 labeled antibodies. Sort gates were restricted to 
the CD4
+
 CD25
high
 (CD4
+
CD25
++
) and CD4
+
CD25
neg
. 
3.9. Suppression assays  
CD4
+
 and CD4
+
CD25
neg
 cells were labeled with 1 M of CFSE.  
1x10
5
 autologous mytomicin-C treated (25g/ml) PBMC plus 2x10
4
 CD4
+
CD25
-
 in 
absence/presence of 2x10
4
 CD4
+
 CD25
high
 Treg were resuspended in 200 l RPMI 
1640 medium and stimulated with coated anti-CD3 (10g/ml) or with the A 
peptide pool (10g/ml).  
Cultures were set up as duplicates in U-bottom wells (COSTAR, Cambridge, MA, 
USA) and incubated at 37° C in a humidified atmosphere with 5% CO2.  
After 5 days cells were harvested and the CFSE signal of gated lymphocytes was 
analyzed by flow cytometry.  
The suppressive capacity of Treg towards responder cells in coculture (Tresp-Treg 
ratio 1:1) was expressed as the relative inhibition of the percentage of CFSE
low 
cells (proliferating [100x (1- %CFSE
low 
CD4
+
CD25
-
 in coculture/ %CFSE
low 
CD4
+
CD25
-
 T cells alone)] for CFSE based measurement of proliferation.  
3.10. Immunofluorescent staining 
PBMCs, previously stimulated with either non-immunogenic peptides or with a pool 
of A peptides, were washed in PBS and stained with anti- CD3, -CD4, -CD8, -
CD14, -CD19, -CD25, -PD-L1 (B7-H1), -PD-1, -CCR7, -CD45RA mAbs for 30
 
min 
at 4°C in the dark. For the analysis of proliferation and of cytokine-secreting cells 
PBMCs were washed once again in PBS and treated with FIX and PERM (FIX & 
PERM Cell Permeabilization kits; eBioscience San Diego, CA, USA), fixed for 10 
min in fixation medium (100l) then washed and resuspended in 100l of 
permeabilization medium with mAbs against the following antibodies: anti- Ki-67, -
FOXP3, -RORc/, -T-bet, - GATA-3, - NFkB, -NFATc1, or with anti-IFN-,-IL-4, -
IL-6, -IL-9, -IL-10, -IL-12, -IL-17, -IL-21, -IL-22, -IL-23, and anti-TGF- mAbs. 
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3.11. Apoptosis  
After being stained with CD4-, CD8- and PD-1-specific mAbs for 30 minutes at 4°C 
in the dark, PBMC were resuspend in ice-cold 1X Binding Buffer (Beckman-
Coulter, Fullerton, CA, USA) plus 10 l of Annexin V and 20 l of 7-AAD viability 
Dye for 15 minutes on ice in the dark. Cells were then resuspended in 400l of 1X 
Binding Buffer and analyzed by flow-cytometry. 
Using a DNA specific viability dye, like the 7-AAD makes possible the distinction 
between early apoptotic and the late apoptotic or necrotic cells. 
3.12. Blocking assay 
Anti-PD-1 or anti-PD-L1 (10g/ml) mAbs were added to cell cultures together with 
the A fragments and left throughout the stimulation period; Annexin V expression 
was evaluated at the end of such period. Mouse IgG1 isotype control antibodies 
were used in A -stimulated cell cultures.  
3.13. Flow staining for PD-1 and FOXP3 of CD4+ CD25high T reg 
Freshly isolated, PBMC were washed and incubated with CD4-, CD25-, and PD-1-
specific monoclonal antibodies for 30 min at 4°C.  
PBMC were then washed and the intracellular costaining of PD-1 and FOXP3 was 
conducted using the FOXP3 staining protocol (eBioscience). Intracellular or surface 
costaining of PD-1 and intracellular FOXP3 was performed on CD4
+
CD25
high
 
(CD4
+
CD25
++
) gated T cell by flow cytometry. 
3.14. Monoclonal Abs  
The monoclonal antibodies used in this study for PBMC stimulation or labelling are 
shown in Table 1.  
3.15. Cytometric analysis 
Analyses were performed using a Beckman-Coulter Cytomics FC-500 flow 
cytometer equipped with a single 15 mW argon ion laser
 
operating at 488 nm and 
interfaced with CXP Software 2.1.  
Two hundred thousand lymphocyte-monocytes were acquired and gated on CD3, 
CD4, CD8, CD14, CD19 or CD25 expression and side scatter properties. Green
 
florescence from FITC (FL1) was collected through a 525-nm bandpass
 
filter, 
orange-red fluorescence from PE (FL2) was collected
 
through a 575-nm bandpass 
filter, deep-red fluorescence from
 
PC5 (FL4) was collected through a 670-nm 
bandpass filter, and blue fluorescence from
 
PC7 (FL5) was collected through a 
770-nm bandpass filters.
 
Data were collected using linear amplifiers for forward 
and
 
side scatter and logarithmic amplifiers for FL1, FL2, FL4 and FL5.
 
Samples 
were first run using isotype control or single fluorochrome-stained
 
preparations for 
color compensation. Rainbow Calibration Particles (Spherotec, Inc. Lake Forest, 
IL) were used to standardize flow-cytometry results in samples obtained over time.  
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3.16. Statistical analysis 
Quantitative data were not normally distributed (Shapiro-Wilk test) and are thus 
summarized as median and Interquartile Range (IQR; 25° and 75° percentile). 
Comparisons between groups were analyzed to evaluate immunological 
differences. Kruskal-Wallis analysis of variance was performed for each variable; 
Comparisons among the different groups were made using a two-tailed Mann-
Whitney test performed for independent samples. Data analysis was performed 
using the SPSS statistical package (SPSS Inc. Chicago, Illinois, USA). 
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4. RESULTS 
4.1. Treg cells in peripheral blood of AD or MCI patients and HC 
Treg cells (CD4
+
/CD25
high
/FOXP3
+
) can be classified into two different 
subpopulations, naïve and activated, on the basis of the cytoplasmic or 
expression of the PD-1 protein, respectively. We examined these three 
populations, CD4
+
/CD25
high
/FOXP3
+
 (Treg), CD4
+
/CD25
high
/FOXP3
+
/PD-1
+
 
(activated Treg), and CD4
+
/CD25
high
/FOXP3
+
/PD-1
neg
 (naïve Treg) in the 
blood of all MCI and AD patients, comparing the results with those of 30 
age-matched healthy controls (HC). Representative results are presented in  
 
 
Figure 1. 
Results showed that CD4
+
/CD25
high
/FOXP3
+
 were significantly increased in 
patients with a diagnosis of either MCI (median percentage= 1.5%) or AD (median 
percentage= 1%) compared to HC (median percentage= 0.01%; p< 0.001 in both 
cases), but no differences were observed between the two groups of patients. 
Activated CD4
+
/CD25
high
/FOXP3
+
/PD-1
+
 Treg lymphocytes were increased in both 
MCI (median percentage= 0.05%) and AD patients (median percentage= 0.2%) 
compared to HC (median percentage= 0.01%; p= 0.01 and p< 0.001 respectively), 
a significant higher percentage was observed in AD compared to MCI (p= 0.02). 
In contrast with these results, CD4
+
/CD25
high
/FOXP3
+
/PD-1
neg
 (naïve) Treg cells 
were significantly augmented in MCI patients alone (median percentage= 1.9 %). 
This increase was highly significant compared to both HC individuals (median 
percentages= 0.01%; p<0.001) and patients with a diagnosis of full-blown AD 
(median percentage= 0.03%; p=0.006) (Figure 2). 
These results suggest that the increase of naïve Treg cells, the regulatory T 
lymphocytes endowed with the strongest suppressive abilities, is an immunological 
feature that characterizes MCI individuals, distinguishing them from patients with 
full-blown AD.  
4.2. A pool-stimulated proliferation in AD, MCI and HC 
A accumulation is strongly suspected to activate microglia and astrocytes 
mediating inflammation, a process suggested to be at the basis of neuronal 
damage in AD. A-stimulated proliferation was measured in all the subjects 
enrolled in the study.  
To this end, peripheral blood cells of AD, MCI, and HC individuals were stimulated 
with either a pool of A immunogenic peptides or with a pool of non-immunogenic 
(control) peptides. Cell division was subsequently evaluated using CFSE staining. 
Results indicated that the Apool-stimulated proliferation of CD4
+
 T lymphocytes, 
expressed as a stimulation index (S.I.), was significantly augmented in AD (S.I. 
median value= 2.5) compared to MCI patients (S.I.=0.02; p=0.007), with the lowest 
values being observed in HC (S.I.=0.01; p<0.001 vs. AD). 
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A pool-stimulated S.I. of CD8
+
 T lymphocytes were similarly greatly increased in 
AD compared to MCI patients and HC (S.I.: AD=2.0; MCI= 0.01; HC=0.01). This 
difference was statistically significant when AD patients were compared to HC 
(p<0.001)(Figure 3). No proliferation was observed by cells of any of the groups 
enrolled in the study upon stimulation with the pool of non-immunogenic control 
peptides.  
 
4.3. Suppression of A pool and anti-CD3-stimulated 
proliferation by Treg 
The ability of Treg to suppress the proliferation of antigen- and anti-CD3-stimulated 
proliferation was analyzed in both groups of patients enrolled in the study 
compared to those obtained in HC. CD4
+
CD25
high
 Treg cells were isolated from 
freshly drawn peripheral blood, (PD-1-based sorting is not technically possible) and 
Treg-depleted cells were stimulated with either the pool of immunogenic 
Apeptides or with anti-CD3. Treg were then added back in a 1:1 ratio of 
Tresp/Treg lymphocytes.  
Results obtained upon stimulating cells with the pool of immunogenic Apeptides 
indicated that the suppressive ability of CD4
+
CD25
high
 Treg cells on activated cells 
was significantly higher in MCI (median percentage = 40%) compared to AD (21%; 
p= 0.04). These values were significantly higher also compared to those observed 
in HC, in whom the stimulation of peripheral blood with the pool of immunogenic A 
peptides did not elicit the generation of A-specific Teffector cells (p< 0.001 in both 
cases).  
Finally, results obtained in anti-CD3-stimulated cell cultures showed an augmented 
suppression activity of CD4
+
CD25
high
 Treg on activated cells in AD (median 
percentage = 50%) compared to MCI (19%) patients and HC (25%); these 
differences did not reach statistical significance. These results are presented in 
Figure 4. 
4.4. PD-1-expressing CD4+ and CD8+ T cells in A-stimulated 
PBMC 
A-stimulated lymphocytes were analyzed in PBMC isolated from the peripheral 
blood of all patients and controls. Results showed that A-stimulated and PD-1-
expressing CD4
+
 T lymphocytes were significantly decreased in AD and MCI 
patients compared to controls (p= 0.01 and p=0.009, respectively); an analogous 
trend, that nevertheless did not reach statistical significance, was observed for PD-
1-expressing CD8
+
 T lymphocytes (Figure 5). 
In contrast with these results, PD-1 mean fluorescence intensity (MFI) was similar 
on CD4
+
 and CD8
+
 T lymphocytes of AD, MCI, and HC individuals (Table 2). 
4.5. PD-L1-expressing CD14+ and CD19+ cells 
PD-1 on T lymphocytes binds PD-L1 on the surface of APC. Since we detected a 
decreased expression of PD-1 on T cells of AD and MCI patients we next analyzed 
PD-L1 expression on APC (CD19
+
 and CD14
+
) in A-stimulated-PBMC of all the 
patients enrolled in the study. Results showed that, whereas the percentage of PD-
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L1-expressing CD14
+
 and CD19
+
 cells was similar in patients and controls, PD-L1 
MFI was significantly decreased in CD14
+
 APC of AD and MCI individuals 
compared to controls (p=0.008 and p=0.005 respectively)(Figure 6)(Table 2). 
4.6. IL-10-secreting and PD-L1-expressing CD14+ and CD19+ 
cells 
The interaction between PD-1 and PD-L1 results in IL-10 production. Since 
previous results had indicated that fewer PD-1-expressing CD4
+
 T lymphocytes 
can engage reduced amounts of PD-L1 on CD14
+
 APC in AD and MCI, we 
expected to observe a reduced production of IL-10 by the interaction of the cells of 
these patients. Actually, data showed that A-stimulated and IL-10-secreting 
CD14
+
 cells were significantly decreased in AD and MCI compared to HC (p=0.03 
and p=0.01 respectively), as we expected (Figure 7). 
We next analyzed IL-10 production in CD14
+
/PD-L1
+
 and in CD19
+
/PD-L1
+
 gated 
populations, i.e. we quantified IL-10 producing cells in response to A within the 
pool of PD-L1-expressing CD14
+
 and CD19
+
 APC. Results showed that IL-10 
producing CD14
+
PD-L1
+
 cells were significantly decreased as well in AD and MCI 
patients compared to controls (p=0.02 and p=0.03 respectively)(Figure 8). 
4.7. A-stimulated apoptosis and proliferation 
The interaction between PD-1 and PD-L1 results in the apoptosis of antigen-
specific cells. We analyzed this parameter by evaluating A-stimulated and 
Annexin V-expressing, as well as PD-1- and Annexin V-co-expressing T 
lymphocytes in all the individuals enrolled in the study.  
Results indicated that Annexin V-positive CD4
+
 A-specific T lymphocytes were 
reduced in AD and MCI compared to HC (p= 0.03 in both cases). A-specific- 
Annexin V- and PD-1-co-expressing CD4
+
 T lymphocytes were significantly 
reduced as well in AD and MCI patients compared to controls (p= 0.04 in both 
cases), indicating that these pathologies are associated with diminished amounts 
of A-specific CD4
+
 T cells that undergo apoptosis (Figure 9). 
As A-specific CD4
+
 T lymphocytes of AD and MCI patients are less susceptible to 
apoptosis it is reasonable to expect that these cells would proliferate more upon in 
vitro stimulation with A- peptides. This was indeed the case as the fraction of A- 
specific Ki67
+
 CD4
+
 T lymphocytes was significantly higher in AD and MCI patients 
compared to controls (p=0.02 and p=0.006 respectively)(Figure 10). 
Finally, to confirm that the apoptosis of A-specific T cells is mediated by the PD-
1/PD-L1 interaction, we performed a blocking assay pre-incubating lymphocytes 
with a PD-L1-specific blocking antibody. Results showed that impeding the PD-
1/PD-L1 interaction results in a significant reduction of Annexin V-expressing 
lymphocytes, thus supporting the pivotal role played by the PD-1/PD-L1 loop in 
inducing the apoptosis of A-specific T cells (p= 0.04 in both cases). These results 
are presented in Figure 11. 
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4.8. CD4+ T helper subsets in A peptides-stimulated cell 
cultures 
PBMC obtained from 38 AD and 34 MCI patients as well as from 40 age-and-sex-
matched HC were stimulated in vitro with A-peptides. Cytofluorimetric analyses 
were used to detect the percentage of CD4
+
T lymphocytes producing IFN, IL-4, 
IL-9, IL-17, IL-21 and IL-22 at the end of the culture period.  
Results showed that, whereas most cytokine-producing CD4
+
 T helper subsets 
were similar in MCI and HC, A-stimulated IL-9-, IL-21- and IL-22- producing CD4
+
 
lymphocytes were significantly augmented in AD patients (vs HC p<0.001 p=0.007, 
and p=0.009 respectively)(Figure 12). Notably, the MFI of A-stimulated CD4
+
 T 
cells producing IL-21, IL-22, and IL-9 was significantly increased as well in AD 
patients (Table 4). 
Thus, IL-21 and IL-22- cytokines produced by Th-17 cells- as well as IL-9, a 
cytokine generated by Th-9 lymphocytes, were significantly released in AD patients 
upon in vitro stimulation of cells with A-peptides.  
These results suggest that in this disease the A-specific immune response is 
skewed favoring the differentiation of the inflammation-associated Th-17 and Th-9 
subsets of T cells. 
 
4.9. Cytokine-production in CD14+ cells in A-stimulated cell 
cultures 
Multiple cell types mediate the immune response. To approach the in vivo situation 
we examined cytokine-expressing CD14
+
 monocyte/macrophages in A-peptide-
stimulated cell cultures. Results indicated that IL-6- and IL-23-producing CD14
+
 
cells were significantly augmented in AD patients compared to HC (p=0.01 and 
p=0.004 respectively); IL-23-producing cells were augmented in MCI individuals as 
well even if this difference did not reach statistical significance. Notably, IL-10 
producing CD14
+
 cells as well as the MFI of these cells were significantly reduced 
both in AD and MCI patients compared to HC (Figure 13) (Table 4). Finally, IL-12-
producing cells (IL-12 drives differentiation toward the Th-1 lineage) and TGF- 
producing monocytes were comparable in all individuals.  
Monocyte/macrophages-produced IL-6 and IL-23 stimulate the differentiation and 
stabilization of naïve CD4
+
 T cells toward the Th-17 pathway. Thus, both cytokines 
eliciting the generation of Th-17 lymphocytes and those produced by such 
lymphocytes were increased in AD patients. Importantly, the Th-17-supported 
inflammatory milieu detected in AD was not counterbalanced by IL-10, a cytokine 
endowed with potent anti-inflammatory properties, whose production is reduced in 
cells of AD patients. The observation that IL-10 generation was decreased in MCI 
as well, in the absence of an increased activity of Th-17 and Th-9 cells, suggests 
that increased production of pro-inflammatory cytokines, rather that reduced 
generation of anti-inflammatory cytokines characterizes A- specific immune 
response in AD. 
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4.10. Transcription factor-expressing CD4+ T cells in A peptide- 
stimulated cell cultures 
Distinct transcription factors (TF) are activated during the differentiation of Th cells 
into different functional subsets. We analyzed the know TF in all the individuals 
enrolled in the study. Results showed that both RORc/ and NFATc1, TF involved 
in the differentiation of naïve cells toward the Th-17 lineage and preferentially 
expressed by memory T lymphocytes, respectively, were significantly increased in 
AD patients compared to HC (p=0.01 for both); the MFI for these two TF was 
significantly augmented as well in AD individuals (Table 4). These results confirm 
that the Th-17 differentiation machinery (differentiating cytokines, Th-17-produced 
cytokines, TF) is up- regulated in AD.  
RORc/, but not NFATc1, was increased in A-stimulated CD4
+
 T cells of MCI as 
well compared to HC (p=0.03). Notably GATA-3, a TF involved in the differentiation 
of Th-2 cells, was also significantly augmented in MCI individuals alone compared 
to AD (p=0.01 vs. AD; p= 0.004 vs. HC). Th-2 cells play an anti-inflammatory role, 
these results therefore seem to indicate that in MCI an immune mechanism that 
obstacles Th-17-mediated inflammation is present; this mechanism is lost in AD. 
Finally, T-bet-expressing cells (T-bet is the Th-1-associated TF) were comparable 
in all individuals tested.   
These results are presented in Figure 14. 
 
4.11. Naïve and memory T cell subsets   
Antigen-stimulated T lymphocytes mature into distinct memory phenotypes. To 
investigate such phenotypes we measured naïve, central memory (CM), effector 
memory (EM), and terminally differentiated (TD) CD4
+
 T lymphocytes in the 
peripheral blood of all the individuals enrolled in the study. The percentage of all 
cells was similar in unstimulated cultures; a much more interesting pattern was 
observed when PBMC were stimulated in vitro with A-peptides.  
To summarize: naïve (CCR7
+
/CD45RA
+
) and CM (CCR7
+
/CD45RA
neg
) CD4
+
 T 
lymphocytes were decreased whereas EM (CCR7
neg
/CD45RA
neg
) and TD 
(CCR7
neg
/CD45RA
+
) CD4
+
 T lymphocytes were augmented in AD and MCI 
compared to HC. Results are presented in Table 3. 
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5. DISCUSSION 
The etiology of Alzheimer’s disease (AD), a condition characterized by progressive 
dementia with gradual loss of cognitive function, is still unresolved but increasingly 
evidence indicate an involvement of the immune system and neuroinflammatory 
processes such as an increase of proinflammatory cytokines, activation of 
microglia and changes or defects in immune responses in the pathology. 
A multitude of factors are implicated in immune response such as cytokines, the 
complement system, acute phase reactants and cellular elements. While this 
system is an effective and potent response to acute challenges, it is imperative that 
it be tightly regulated over the longer term. Dysregulation and chronic activation 
can have detrimental effects on the host. T cells are activated and display memory 
phenotype in AD patients; these cells can be detected both in the periphery and as 
infiltrates in the brain [96], suggesting that an activation of the immune response is 
present in AD. It is still ill-understood if these cells play a beneficial or a detrimental 
role in the disease. Nevertheless the observations that: 1) therapeutic approaches 
based on the use of anti-inflammatory drug are mildly effective in this disease, and 
2) amyloid-beta immunization could result in meningoencephalitis in humans favour 
the interpretation that neuroinflammation plays a pathogenic role in the disease. 
Specifically, a breakdown of peripheral tolerance could lead to an activation of 
autoreactive lymphocytes like CD4
+
 Th-1, Th-17 and Th-9 cells which may 
contribute to neuroinflammation progression [24]. 
In this context, suppressive mechanisms mediated by Treg cells [262] and 
inhibitory mechanisms mediated by PD-1/PD-L1 pathways [70] play a remarkable 
role in immunological tolerance maintaining. 
 
Recent data has led to a ready distinction of two populations of Treg cells: naïve 
Treg cells, which retain PD-1 in intracellular compartments, and activated Treg 
cells, which coexpress surface CD25 and PD-1 (activated Treg). Moreover, Treg 
translocate PD-1 to the cell surface when stimulated via the TCR [27]. This allows 
ready distinction of two populations endowed with different suppressive capacities: 
CD4
+
/CD25
high
/FOXP3
+
/PD-1
neg
 naïve Treg cells, provided with stronger 
suppressed properties, and CD4
+
/CD25
high
/FOXP3
+
/PD-1
+
 activated Treg cells [27]. 
Thus we examined these Treg cells subsets in patients with a diagnosis of either 
MCI or AD; results herein indicate that development of AD is associated with lower 
quantities of circulating Treg cells, and, in particular with reduced percentages of 
naïve Treg. These quantitative alterations are associated with qualitative changes, 
summarized as an increased amyloid- specific proliferation and a reduced ability 
of Treg to suppress such proliferation. These results, together with the preliminary 
observation that the lowest percentages of all subpopulations of Treg cells are 
seen in patients with severe AD, lend support to the inflammatory origin of AD and 
suggest that alterations in Treg lymphocytes play a pivotal role in the inflammation 
associated with AD. 
The brain is an immunologically privileged site (a “sanctuary”) protected and 
isolated from organism’s immune reaction by the BBB (blood-brain barrier). BBB is 
a complex cellular gate, which regulates tightly the transport of ions, solutes and 
cells into and from the central nervous system.  
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The term “reactive gliosis” has been used to describe immune activation of glial 
cells, including microglia and astrocytes, which exist in a quiescent (resting) state 
in the healthy CNS. Following neural insult, these cells become activated and 
undergo hypertrophy accompanied by increased expression of cell surface immune 
antigens. Concomitantly, both activated microglia and astrocytes synthesize and 
release a myriad of pro-inflammatory cytokines, chemokines, complement proteins, 
proteinases, and reactive oxygen species. While this neuroinflammatory response 
may be beneficial for clearing infection and initiating tissue repair mechanisms, if 
left unresolved, it exposes sensitive neurons to elevated levels of potentially toxic 
molecules, leading to bystander injury. In fact, there is mounting evidence that 
chronic neuroinflammation plays a critical role in the pathoetiology of various 
neurodegenerative diseases including AD, MS, and PD 
[105,115,120,170,263,264]. In addition to CNS endogenous immunity, discrete 
populations of exogenous, peripherally derived immune cells can traffic to the CNS, 
particularly during disease states.  
Normally lymphocytes are able to pass BBB, but physiologically they are not 
numerous in normal brain. Lymphocyte migration into and within the CNS is 
regulated by chemokines and their receptors. Disruption of the integrity of BBB, as 
result of multiple microtrauma, microvascular pathology (as cerebrovascular 
pathology is often associated to AD) and inflammation, can increase permeability 
of BBB, leading to the abolition of the immunological privilege of the CNS. 
To date, such evidence points mainly at an association between various dementia 
forms and disruption of the BBB. During chronic neuroinflammation the release of 
inflammatory mediators from activated microglia increases BBB permeability [88]. 
The observations that: 1) immune cells continuously re-circulate throughout the 
body; and 2) immune cells migrate across the blood-brain barrier (BBB), and the 
BBB is permeable to cytokines, seem to support to our results, conducted in 
peripheral blood. 
So we can hypothesize that the link between T-cells and AD “passes” through 
BBB, meaning that their migration is a result of BBB dysregulation and impairment 
[265,266]. 
Ahas been shown to activate microglia and astrocytes and stimulate them to act 
as immunological mediators [267,268]. A variety of other cell surface proteins are 
upregulated on activated microglia neighboring A plaques. Microglia surrounding 
plaques release cytotoxic molecules such as NO, oxygen radicals, proteases, 
proinflammatory cytokines, including IL-1, TNF and IL6, and expresses MHCI, 
MHCII, CD40 and adhesion molecules [170]. In this context, the up-regulation of IL-
1 enhances blood brain barrier (BBB) permeability facilitating leukocytes 
infiltration [269]. Immune responses thus do occur in CNS and can be driven by 
endogenous (microglia and astrocytes) and/or exogenous (peripheral leukocytes) 
sources and can serve either productive or pathological roles [249]. Peripheral 
monocyte/macrophage recruitment in CNS could limit -amyloid plaques [249,250, 
263]; in addiction activated endothelium or microglia can present A peptides to T 
cells inducing adaptive immune response [105,270]. 
Whether the arrival of T-cells is beneficial or detrimental is ill understood. However 
in the case of massive T-cell response (for instance in A vaccine-related 
meningoencephalitis), the effects seem to overwhelmingly negative. 
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Treg cells have convincingly been shown to modulate immune reactivity and 
inflammation, and quantitative/ qualitative alterations of such cells result in the 
honing of inflammation, favoring autoimmune processes. 
Treg are still relatively unexplored in AD. A recent paper showed an increase of 
such cells (identified as FOXP3 expressing lymphocytes) in AD and in older 
healthy controls; the authors also reported an increased ability of Treg cells of AD 
patients to suppress mitogen-stimulated proliferation in vitro [271]. These data, 
thus, suggest that the frequency of Treg increases with age and is accompanied by 
a stronger suppressive activity. Our data confirm an increase of Treg cells 
(identified as CD4
+
CD25
++
FOXP3
+
) in AD but are in partial disagreement with 
those of Rosenkranz et al., since this increase does not involve PD-1
neg
 Treg 
lymphocyte (naïve Treg), the cells with the highest functional activity, that are 
diminished in AD. Moreover, our results do not confirm that Treg cells are 
increased in older healthy individuals, as we detected a decrease of such cells in 
such individuals. Notably, other authors [272] reported a decreased percentage of 
CD4
+
CD25
high
 cells in AD compared to older controls and an increase of these cells 
was observed in healthy elderly groups [273]. The apparent discrepancy between 
these data and the ones herein is explained by the fact that we identified Treg cells 
by different and more specific markers. Additionally, the age range of our healthy 
control was higher than that of the individuals studied in Larbi A et al., 2009. 
Suppression assay provided data of Treg cells functional activity. We observed a 
significant increase of Treg mediated-suppression of A specific proliferation in 
MCI and AD compared to HC. This result could be seen either as protective or as a 
harmful response, contributing to disease progression. The latter hypothesis is less 
credible because Treg mediated suppression is decreased in AD compared to MCI, 
suggesting an association between disease worsening and decrease of Treg 
suppressive capacity. The previous observation that CD8
+
CD28
neg
 lymphocytes, 
cells known to have a suppressor/regulatory function resulting in T helper 
unresponsiveness [274], are also significantly reduced in AD patients, further 
supports the concept that a generalized impairment of the suppressor/ regulatory 
ability of T lymphocytes is present in AD. 
Results from the analysis of amyloid--specific proliferation in all the groups of 
individuals enrolled in the study indicate that amyloid--specific proliferation is 
significantly higher in AD compared to MCI patients; the in vitro amyloid- peptides 
stimulated- generation of effector T cells was also greatly increased in AD 
individuals. Interestingly, the observation that no amyloid--specific effector cells 
were elicited in healthy controls suggests that normal aging is clearly distinct from 
MCI, underlining the hypothesis that individuals with MCI are much more similar to 
AD patients than they are to age-matched healthy controls.  
The suppressive ability of Treg on amyloid-peptides-stimulated proliferation was 
also significantly reduced in AD compared to MCI individuals. Notably, as sorting of 
PD-1
neg
 cells is not technically
 
possible, suppression was measured using 
CD4
+
CD25
high
 cells isolated from
 
freshly drawn blood; as a consequence we did not 
formally measure the
 
suppressive capacity of PD-1
neg
 Treg cells. Nevertheless,
 
the 
observation that the percentages of PD-1
neg
 Treg cells
 
are significantly different in 
MCI, AD, and HC individuals allows
 
the speculation that the different suppressive 
abilities we
 
observed are secondary to the diverse percentages of PD-1
neg 
Treg 
cells detected in each one of these subpopulations.  
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The data herein indicate that Treg cells, and in particular, PD-1
neg 
Treg cells might 
play an important role in the pathogenesis of AD: loss of such cells and of their 
functional ability is associated with development of AD.  
Treg cells mediate their effect via two complementary mechanisms: IL-10-mediated 
functional impairment of immune cells and induction of apoptosis of such cells. In 
this light it is interesting to notice that: 1) amyloid--stimulated IL-10 production has 
been shown to be reduced in AD compared to healthy individuals [255] and 2) 
particular SNP of the IL-10 gene associated with low IL-10 production are 
significantly over expressed in AD [275].  
In this context it has become interesting to evaluate PD-1-mediated apoptosis of 
amyloid--specific cells in patients with a diagnosis of either MCI or AD.  
The interaction between PD-1 and PD-L1 dampens immune responses, limiting 
inflammation. Data herein indicate that, upon A-stimulation, PD-1 expression is 
significantly reduced in CD4
+
 T cells of AD and MCI patients compared to HC. Low 
levels of PD-1 can bind low quantities of PD-L1 molecules on the surface of CD14
+
 
APC. This leads to a reduced production of -stimulated IL-10, an increased 
proliferation of A-stimulated T lymphocytes, and a reduced susceptibility of such T 
lymphocytes to apoptosis. To summarize, data herein demonstrate that an 
inflammatory milieu is present in MCI and AD and provide a molecular explanation 
for the generation of such milieu. 
Since the interaction between PD-1 with PD-L1 can negatively regulate 
autoreactive T- and B-cells and plays a pivotal role in the maintenance of 
tolerance, it is conceivable that an imbalance between positive and negative 
signals may contribute to the onset of a variety of autoimmune diseases [276]. 
Recent data show that the ligation of PD-L1 by naïve T lymphocytes limits effector 
cells responses and prevents the triggering of immune-mediated tissue damage 
[70,277,278,]. This is achieved through two complementary mechanisms: the 
generation of IL-10, a powerful anti-inflammatory cytokine, and the limitation of the 
proliferation of antigen-specific cells, possibly via the triggering of apoptosis of such 
cells. In fact, PD-1 is abundantly expressed in diseases associated with increased 
IL-10 generation such as lung, ovary, and colon carcinoma [279] and HIV infection 
[280]. In this context it is important to underline that decreases in IL-10 production 
have been described in AD patients, in whom the IL-10 gene SNPs associated with 
higher production of this cytokine are also less frequently detected [281]. Notably, 
increases in IL-10 have been described in non-demented healthy elderly 
individuals [282], and a particular genotype resulting in higher levels of IL-10 was 
found to be associated with longevity [283].  
IL-10 dampens immune responses and suppresses antigen-stimulated 
proliferation; together with the induction of apoptosis of antigen-specific cells these 
PD-1/PD-L1-mediated mechanisms play essential roles in modulating positive and 
negative selection in the thymus [284] and in the protection of immune privileged 
sites, such as the placenta [285] and the eye, from immune responses [286]. 
The down-regulation of these mechanisms seen in MCI and AD result in an 
increased proliferation of A-stimulated T lymphocytes, as these cells are neither 
induced to undergo apoptosis, nor anergized by IL-10.  
The pivotal role played by the PD-1/PD-L1 interaction in inducing the apoptosis of 
A-specific CD4
+
 T lymphocytes is confirmed by the observation that apoptosis is 
blocked by pre-incubation of these cells with an anti-PD-L1 antibody. The net result 
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of the down-regulation of the PD-1/PD-L1 pathway seen in AD and MCI is an 
increased percentage of A-specific CD4
+
 T cells that proliferate vigorously; in vivo 
this is associated with neuroinflammation, and is likely to be a negative factor in the 
pathogenesis of MCI and AD. Notably, no differences were seen when MCI and AD 
patients were compared, suggesting that similar immunologic abnormalities are 
present in both conditions, and that both conditions are different from the situation 
present in healthy aging individuals. Because some, but not all MCI will progress to 
AD, these data suggest that inflammation is a necessary first step associated with 
the appearance of cognitive impairment, but inflammation alone is not sufficient to 
cause AD. In particular, the systemic inflammation observed in this pathology 
seems to play an important role in recruiting monocyte derived blood cells in the 
CNS in attempt to dampen neuroinflammation; treatment with anti-inflammatory 
drugs could lead to a down-modulation of such recruitment [287]. The mechanism 
used by monocytes to suppress local inflammation could rely on the activation of 
inhibitory pathways, including the one described herein that rotates around the PD-
1/PD-L1 axis and is at least partially mediated by IL-10 production.  
The fact that data herein stem from analyses performed in peripheral blood 
lymphocytes and not in cells circulating in the cerebro-spinal fluid (CSF) could 
apparently weaken our results. CSF examination in our patients was performed 
only when necessary to exclude reversible causes of dementia. Nevertheless, the 
observations that: 1) immune cells continuously re-circulate throughout the body, 2) 
immune cells migrate across the blood-brain barrier (BBB), and 3) the BBB is 
permeable to cytokines, seem to by-pass such criticism, lending support to our 
results. Recent studies have observed that myelin basic protein-specific and PD-1-
expressing
 
T lymphocytes, as well as PD-L1-expressing CD19
+
 cells are 
significantly reduced during the acute phase of relapsing-remitting multiple 
sclerosis (MS) patients, another neurological disease characterized by extensive 
inflammation [288]. 
It was shown that, beside PD-L1, PD-1 could bind a second protein, PD-L2, on the 
surface on non-T cells [289], but, whereas PD-L1 is constitutively expressed on a 
wide range of hematopoietic and non-hematopoietic cells, PD-L2 is exclusively 
expressed in DC, macrophages and mast cells [71]; thus did not analyze the 
expression of PD-L2 in our patients. 
Both CD14
+
 monocyte/macrophages and CD19
+
 B cells are professional APC; both 
cells can optimally stimulate T lymphocytes-mediated immune responses. Whereas 
the impairment in PD-L1 expression mostly involves CD19
+
 cells in MS, the CD14
+
 
population plays the leading role in AD and MCI. This observation is interesting 
given the significant role played by these cells in AD and MCI. Thus, the 
recruitment of peripheral CD14
+
 cells in the CNS was suggested to be an attempt 
to hamper the generation of amyloid- plaques [263] and, together with endothelial 
and microglia cells, CD14
+
 cells were shown to present A peptides to T cells 
inducing adaptive immune response within the CNS [105,269,290]. Within this 
milieu, the activation of A- specific inhibitory mechanism by monocytes expressing 
PD-L1 and producing IL-10 would result in the dampening of neuroinflammation. 
This pathway seems to be defective in AD and MCI patients.  
Evidence for the presence of immune activation in the peripheral blood and in the 
CNS of AD patients are accumulating [96,291]. 
Infiltration of peripheral blood cells into the normal brain is usually very low. A 
number of CNS disorders, brain injury, or systemic infections [292] is accompanied 
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by infiltration of the brain by peripheral monocytes, macrophages, or T 
lymphocytes.  
To better define the functional and phenotypic profiles of T lymphocytes in AD we 
analyzed cytokines, transcription factors, and post-thymic differentiation pathways 
comparing results obtained in AD to those of MCI and HC. To measure antigen-
specific responses we stimulated cells with A peptides, the protein whose 
deposition triggers neuroinflammation and initiates the pathogenesis of AD.  
Results herein show that, whereas neither Th-1-associated TF nor cytokines are up 
regulated in AD, the activity of the molecular and protein machinery associated with 
the differentiation of Th-17 lymphocytes, as well as cytokines produced by these 
cells, is increased in AD but not in MCI. Thus, monocyte/macrophages (MM)-
producing IL-6 and IL-23, the number of RORc/-expressing cells, and the 
production of IL-21 and IL-22, were all augmented in AD compared to MCI and HC. 
Notably, IL-9, the effector cytokine produced by Th-9 lymphocytes, was 
significantly increased as well in AD patients alone, indicating that, beside Th-17, 
A-specific Th-9 lymphocytes are upregulated in AD. Finally, A-specific, late stage 
differentiated, effector CD4
+
 T lymphocytes were significantly increased in AD 
patients. AD-associated neuroinflammation can be therefore summarized as being 
characterized by a complex impairment of the immune response, with a profound 
skewing favoring inflammatory and effector responses.  
Compared to the massive alterations seen in AD, the situation observed in MCI 
individuals is only marginally altered. Thus, in MCI, A-specific late stage effector 
CD4
+
 T lymphocytes accumulate and the only cytokine alteration seen is a 
decrease in IL-10 production, also present in AD, that is nevertheless not 
accompanied by an increased generation of pro-inflammatory cytokines. Whereas 
the activity of both RORc/ and NFATc1 was augmented in AD, that of RORc/ 
alone was increased in MCI individuals. In these subjects an increased activity of 
GATA-3, the TF associated with Th-2 differentiation, was also observed. In MCI, 
thus: 1) Th-17 cells are not activated (the production of IL-6, IL-23, and IL-21 is not 
increased) even in the presence of an accumulation of RORc/; and 2) IL-10 
production by MM is reduced even if GATA-3 is increased. These puzzling results 
suggest alternate hypothesis. Thus: 1) RORc/ activation could result in the 
production of Th-17-associated cytokines and neuroinflammation only if GATA-3 is 
not activated as well, or, alternatively, 2) neuroinflammation could only develop in 
the presence of an upregulation of both Th-17 and Th-9. These data also suggest 
that the late stage differentiated effector lymphocytes that accumulate in MCI and 
in AD could be qualitatively different in these two conditions because the cytokine 
milieu in MCI is characterized by low amounts of IL-21 and IL-9 and/or 
alternatively, because NFATc1 is not increased in these patients.  
 
Recent studies have demonstrated that naive CD4
+
 T cells contain minimal levels 
of NFATc1 whereas accumulation of this NFATc1 in CD4
+
 memory T cells was 
demonstrated to optimize cytokine gene expression, the situation observed in a 
memory immune response [293]. The higher percentage of A-stimulated and 
NFATc1-expressing CD4
+
 observed in AD patients, together with the increase of 
IL-21, IL-22, and IL-9, and the skewing toward more differentiated  (EM and TD) 
subpopulations of CD4
+
 T lymphocytes, thus supports the idea that a chronic A-
mediated stimulation of immune responses is present in AD.  
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Taken together these results indicate that MCI individuals are much more similar to 
HC that to AD patients; these data also suggest that the immunological difference 
between MCI and AD resides in the lack of activation of Th-17 and Th-9 T cells 
subsets seen in MCI individuals. Thus increased inflammation together with a 
decreased production of the anti-inflammatory cytokine IL-10 is associated with 
AD. IL-10 is an anti-inflammatory cytokine that inhibits the production of pro-
inflammatory cytokines such as IL-6 and TNF-. In IL-10 gene-deficient mice, an 
overproduction of inflammatory cytokines and the development of chronic 
inflammatory diseases have been noted [294]. The anti-inflammatory cytokine IL-
10 may reduce inflammation in brain [295] by suppressing the expression and 
production of inflammatory cytokines and their receptors. An imbalance of pro-
inflammatory cytokines and anti-inflammatory cytokines may therefore be an 
important phenomenon in AD. 
In this context it is important to underline that decreases in IL-10 production have 
been described in AD patients, in whom the IL-10 gene SNPs associated with 
higher production of this cytokine are also less frequently detected [281]. Higher 
levels of IL-10 have also been observed to have a protective effect in animal 
models of AD [296] and attenuation of Alzheimer’s disease-like pathology following 
immunotherapy in murine models is associated with increased levels of IL-10 [297]. 
Data herein nevertheless indicate that decreased production of IL-10 by itself does 
not associate with AD: an inflammatory milieu is necessary. 
The presence of an inflammatory milieu in AD patients was confirmed by the 
observation that IL-6- and IL-23- producing MM were significantly increased in AD 
patients. These cytokines are involved in the differentiation, maintenance and 
stabilization of Th-17 cells, respectively. IL-6 is increased in plasma of patients with 
AD [298] and is expressed in brain cortical plaques [299,300]. Interleukin-23 was 
shown to enhance the pathogenic potential of myelin-specific T cells in the 
induction of autoimmune encephalomyelitis [301]. IL-23 is a potent inflammatory 
cytokine also known to enhance the generation of IL-17 by Th-17 cells and to 
maintain the expression of IL-17 in activated Th-17 cells [302]. 
IL-17 production was not augmented in our patients in the face of an increased 
generation of IL-23; this confusing result could be explained by the observation 
that, whether the expression of the lineage-specific transcription factor 
RORc/leads to Th-17 lineage commitment [13], the population of cells 
designated as Th-17 is not homogeneous. Th-17 cells comprise a wide spectrum 
with a range of effector phenotypes. Although these cells collectively produce 
characteristic Th-17 cytokines, not all cytokines are produced by each individual 
cell in the population but different “functional Th-17 subsets” can prevail. Th-17 
cells in particular exhibit a high degree of plasticity in terms of cytokines produced, 
a property that is dependent on the surrounding cytokine milieu in which they 
develop [303].  
Our results indicate an activation of Th-17 in AD, as an enhanced expression of 
RORc/ was seen in these patients; these cells produced high amounts of IL-21, 
a cytokine that enhances the effector phase of T-cells responses associated to 
inflammation and tissue damage [304], but not of IL-17. These results seem to 
indicate that a subset of non-IL-17-producing Th-17 cells that specializes in the 
generation of IL-21 and IL-22 plays a role in AD.  
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Moreover, TGF- a cytokine that, together with IL-6, is considered to be a factor 
responsible for initiating the Th-17 differentiation, was not increased in A- 
stimulated CD14
+
 cells of AD patients. Recent studies have showed that Th-17 
cells derived in the presence of IL-23 can occur in the absence of TGF- post-mort 
[305]. These ‘alternative’ Th-17 cells, differentiated in the presence of IL-6, IL-1b 
and IL-23, possess a different expression profile in terms of cytokines, transcription 
factors and surface molecules. When ‘classical’ Th-17 cells, induced by TGF- plus 
IL-6, were compared to the alternatively induced Th-17 cells, the ‘alternative’ Th-17 
cells were more pathogenic. 
Th-17 cells cannot be defined using a narrow schematic, but that there is a wide 
spectrum of Th-17 phenotypes with differences in their cytokine production and 
effector functions. The cytokine environment largely determines the expression of a 
network of different transcription factors that in turn determine the cytokines that 
are produced by Th-17 cells. 
The presence of a multifactorial inflammatory milieu in AD was further confirmed by 
the observation that IL-9 was significantly augmented as well in AD patients.  
This cytokine defines the recently identified subset of Th-9 cells, a distinct 
population of helper/effector T cells that promote tissue inflammation [21].  
Th-9 cells do not express any well-defined transcription factors like T-bet, GATA-3, 
RORc/, and FOXP3, emphasizing that Th-9 cells are different from Th-1, Th-17, 
and Treg populations.  
Th-9 lymphocytes differentiate in the presence of IL-4 and TGF-, and are 
identified by their ability to produce IL-9. These cells were suggested to stem from 
a reprogramming of Th-2 lymphocytes [306,307], to be a unique subset of T 
effector cells [21,22], or, alternatively, to be adaptive Treg cells [83]. Although the 
role of Th-9 cells in human pathology is still under debate, recent evidence suggest 
that they can be involved in allergic and autoimmune phenomena [18].  
IL-9 could be either inflammatory or regulatory, depending on the context and the 
source of the producing cells [308,22] as it influences both Th-17 cell differentiation 
and Treg suppressive activity via the interaction with STAT3 and STAT5 
respectively [309,310]. Thus, by simultaneously activating STAT3 and STAT5, IL-9 
influences the balance between Th-17/Tregs and the development of the immune 
responses in vivo. 
Recent results indicating a reduction of Treg cells and an impairment of their 
activity in AD patients [272] seem to indicate that such balance is altered in favour 
of Th-17 in AD patients. 
Post-thymic T lymphocyte maturation of A-specific lymphocytes was also clearly 
skewed in AD and MCI. Thus, effector memory (EM) and terminally differentiated 
(TD) lymphocytes were increased in both groups of patients compared to HC. EM 
cells differentiate from central memory (CM) cells in the presence of antigen and 
cytokines such as IL-7; if the antigenic load is high, EM differentiate into TD: 
terminal effector cells [311]. The situation seen in AD and MCI can therefore be 
summarized as follows: 1) higher concentrations of A induce the differentiation of 
naïve cells into CM; 2) the continuous presence of an elevated antigenic load 
induces the further differentiation of CM into EM and TD. Notably, the increased 
expression of NFATc1 seen in AD but not in MCI would stabilize the cytokine 
secretion by these cells that characterizes AD individuals. Recent data show 
increased quantities of antigen presenting cells expressing MHC class II- A 
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complexes in murine models of AD [306]; it will be interesting to verify if a similar 
phenomenon can be detected in AD and MCI patients: this could justify the 
accumulation of A-specific late stage memory cells seen in these conditions. 
Data herein shed light on the nature of AD-associated neuroinflammation driven by 
Th-17 and Th-9 cells. A better understanding of the complexity of this phenomenon 
could facilitate the search for novel therapeutic strategies. 
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6. CONCLUSIONS 
Neuroinflammation is a complex process that has both beneficial aspects in 
maintenance of brain homeostasis and injury resolution, but also can be 
detrimental if sustained chronically, over years and decades. In the latter case the 
activated brain immune pathways can cause debilitation or death to otherwise 
healthy tissue collateral to sites of injury or histological insult (e.g., amyloid plaques 
and NFTs in the case of AD). Despite early epidemiological evidence that chronic 
use of non-steroidal anti-inflammatory drugs diminished the risk for AD, clinical 
intervention trials have thus far failed to slow disease progression or provide 
convincing evidence of symptomatic improvements in patients with early or 
moderate AD.  
To clarify the role of neuroinflammatory processes suggested to be associated with 
Alzheimer’s Disease we performed extensive immunophenotypic and functional 
analysis of amyloid-beta stimulated PBMCs in patients with a diagnosis of AD 
compared to MCI and aged-matched healthy individual.   Our results indicate that 
the development of AD is associated with a reduction of circulating T reg naïve 
cells, the subpopulation of Treg cells endowed with the strongest suppressive 
ability. These quantitative changes are associated with qualitative changes, 
summarized as an increase of A-specific proliferation and a reduced ability of T 
reg to suppress such proliferation. 
In order to understand the regulation of the balance between inflammation and 
tolerance in AD we studied the PD-1/PD-L1 pathway, which modulates the balance 
between inflammation and tolerance by inducing IL-10 production and apoptosis of 
antigen-specific cells. 
A significant decrease of percentage of amyloid-beta specific and PD-1 expressing 
T cells, as well as of PD-L1- expressing and IL-10-producing CD14
+
 cells was 
observed in AD and MCI patients compared to HC. Results showed an impairment 
of the PD-1/PD-L1 pathway in AD patients, which results in reduced IL-10 
production and diminished apoptosis of A-specific CD4
+
 T lymphocytes. 
The analysis of lymphocytes subpopulations in AD and MCI compared to controls 
highlighted that in AD patients not only an alteration of immunological tolerance is 
present but also a shift in the differentiation of T lymphocytes towards an 
inflammatory phenotype Th-9 and Th-17. 
Our results showed indeed that cytokines (IL-21, IL-23, IL-6) and transcription 
factor (RORc/) involved in the differentiaton of Th-17, as well as cytokines (IL-21, 
IL-22) produced by these cells are all augmented in AD compared to MCI and HC. 
Notably, IL-9, the effector cytokine produced by Th-9 cells, was significantly 
increased as well in AD patients, indicating that, beside Th-17, A- specific Th-9 
lymphocytes are upregulated in AD.  This is accompanied by a shift in post- thymic 
differentiation pathways favoring the accumulation of differentiated, effector T 
lymphocytes. 
The dysregulation of immune tolerance observed in AD patients as the defect in 
PD-1/PDL-1 inhibitory pathway mechanism and the Treg suppression impairment 
leads to a strong activation of A- specific T cell immune response. These finding 
enrich and in part clarify the complex phenomena that orchestrate AD-associated 
neuroinflammation. In conclusion the impairment of the immune response, with a 
profound skewing favoring inflammatory and effector responses seem to play a 
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pivotal role in this pathology. Immunomodulatory approaches direct to restore 
immune tolerance could be envisioned as a way to design new therapeutic 
strategies in delaying progression of disease. 
In this context, the administration of adiponectin (ADN), an adipocytokine with anti-
inflammatory properties produced by adipose tissues, has been demostrated to 
induce immune tolerance in mice. In particular ADN up-regulates PD-L1 expression 
on DC that, in turn, expands/induces the differentiation of CD4
+
T cells towards 
regulatory T cell subpopulation. 
Future studies, evaluating the role of adiponectin in restoring the mechanism of 
immune tolerance in Alzheimer’s Disease patients, could allow a better definition of 
early prognostic biomarker leading to novel therapeutic strategies. 
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8. TABLES AND FIGURES 
Table 1 
 
mAbs clone isotype source company fluorescence 
AV   IgG1k mouse Beckman-Coulter FITC 
BDNF 35909 IgG1 mouse R&D Systems PE 
CCR7 3D12 IgG2a,k rat BD PE 
CD14 RM052 IgG2b mouse Beckman-Coulter PC5 or FITC 
CD19 J3.119 IgG1 mouse Beckman-Coulter PC5 
CD25 B1.49.9 IgG2a mouse Beckman-Coulter ECD 
CD3 UCHT1 IgG1 mouse Beckman-Coulter PE 
CD4 SFCI12T4D11 IgG1 mouse Beckman-Coulter PC7 
CD45RA MEM56 IgG2b mouse Caltag Laboratories FITC 
CD8 SFCI21Thy2D3 IgG1 mouse Beckman-Coulter PC5 
FOXP3 PCH101 IgG2a,k mouse eBioscience FITC 
GATA3 TWAY IgG2b,k rat eBioscience PE 
IFN 4S.B3 IgG1k mouse eBioscience PC5 
IL-10  JES9D7 IgG1 mouse eBioscience PE 
IL-12 27537 IgG1 mouse R&D Systems FITC 
IL-17 BL168 IgG1k mouse Biolegend FITC 
IL-21 3A3-N2 IgG1 mouse eBioscience PE 
IL-22 142928 IgG1 mouse R&D Systems PE 
IL-23 C11.5 IgG1k mouse Biolegend PE 
IL-4 MP4-25D2 IgG1k rat eBioscience FITC 
IL-6 1936 IgG2b mouse R&D Systems FITC 
IL-9 MH9A4 IgG2b,k mouse Biolegend PE 
Ki67 B56 IgG1k mouse BD FITC 
NFATc H-10 IgG1 mouse Santa Cruz Biotech PE 
NFkB C-5 IgG2a mouse Santa Cruz Biotech FITC 
PD-1 MIH4 IgG1 mouse eBioscience PE 
PD-L1 MIH1 IgG1 mouse eBioscience PC7 
RORc/ AFJS-9 IgG2a rat eBioscience PE 
Tbet 39D IgG1 mouse eBioscience PE 
TGF 9016 IgG1 mouse R&D Systems PE 
 Table 1 Monoclonal antibodies used in this study. 
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Table 2  
 
MEDIAN MFI (Interquartile range) 
   AD MCI HC p-value 
CD4+/PD-1+ 15 (5-21) 14 (5-20) 19 (17-21) n.s. 
CD8+/PD-1+ 0 (0.0-0.0) 0 (0.0-0.0) 0 (0.0-0.0) n.s. 
CD14+/PD-L1+ 30 (26-42)* 20 (13-28)** 60 (55-61)*
,
** 
p=0,008* 
p=0,005** 
CD19+/PD-L1+ 0 (0.0-0.0) 0 (0.0-0.0) 0 (0.0-0.0) n.s. 
    Table 2 MFI of PD-1 on A stimulated CD4+ and CD8+ T lymphocytes and of PD-
L1 on CD14
+
 and CD19
+
 cells of patients with a diagnosis of either AD, MCI and 
HC. PD-1 and PD-L1 MFI values were calculated on MFI- positive cells. 
Medians, interquartile ranges and statistical values are shown. 
n.s.= not significant. 
 
 
 
 
Table 3 
 
 
  AD MCI HC p-value 
CD4
+
/CCR7
+
/45RA
+
 
(naive) 
1.4                   
(0.2-9.3)* 
2.2                  
(1-2.6)** 
12.1               
(8.2-16.9)*
,
** 
p=0.03* 
p=0.01** 
CD4
+
/CCR7
+
/45RA
neg
 
(central memory) 
17.1        
(12.3-34.6)* 
11                
(6.1-11.8)** 
38.1                 
(38-41.2)*
,
** 
p=0.04* 
p<0.001** 
CD4
+
/CCR7
neg
/45RA
neg
(effector memory) 
68.6        
(53.7-79.2)* 
73              
(68.5-86.1)** 
35.7           
(30.3-47)*
,
** 
p=0.01* 
p=0.002** 
CD4
+
/CCR7
neg
/45RA
+
 
(terminally 
differentiated) 
4.6            
(2.2-5.5)* 
9                 
(2.4-14)** 
1                  
(0.1-2.7)*
,
** 
p=0.01* 
p=0.04** 
 
Table 3 A- stimulated subsets of CD4
+
 T lymphocytes in patients with a 
diagnosis of AD or MCI and in HC; medians, interquartile ranges and statistical 
values are shown. 
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Table 4 
 
MEDIAN MFI (Interquartile  range) 
    AD MCI HC p-value 
CD4+/T-bet 15 (12.7-18.2) 15 (12-18.5) 12.5 (12-16.75) n.s. 
CD4+/RORc/ 31 (23.5-40.2)* 14 (13.5-18)** 0.0 (0.0-12)*
,
** 
p=0.01* 
p=0.08** 
CD4+/GATA-3 5 (0.0-15)** 21 (8.5-20)**
,
* 6 (0.0-13)* 
p=0.02* 
p=0.03** 
CD4+/NFATc 5 (0.0-20.5)* 0.0 (0.0-16) 0.0 (0.0-12)* p=0.04* 
CD4+/NFkb 0.0 (0.0-15) 0.0 (0.0-13) 0.0 (0.0-12) n.s. 
CD4+/IFN 0.0 (0.0-12) 0.0 (0.0-18) 0.0 (0.0-11.5) n.s. 
CD4+/IL-9 23 (20-25)*
,
** 15 (9-15.7)** 13 (0.0-15)* 
p=0.02* 
p=0.01** 
CD4+/IL-17 0.0 (0.0-15) 0.0 (0.0-17) 0.0 (0.0-12) n.s. 
CD4+/IL-21 12 (0.0-23)* 0.0 (0.0-17) 0.0 (0.0-9)* p=0.02* 
CD4+/IL-22 22 (15-26.5)* 14 (12-22)** 15 (0.0-15)*
,
** 
p=0.001* 
p=0.03** 
CD4+/IL-4 0.0 (0.0-10) 0.0 (0.0-13) 15 (0.0-15) n.s. 
CD14+/TGF 42 (26.2-62.5) 21 (0.0-39) 29 (18-38.5) n.s. 
CD14+/IL-
12p35 
7.5 (0.0-20) 0.0 (0.0-16.7) 13.5 (0.0-22.7) n.s. 
CD14+/IL-23 0.0 (0.0-20) 0.0 (0.0-25) 18.5 (9-25.2) n.s. 
CD14+/IL-6 30.5 (17.2-41.2) 22 (15-36) 28 (16.7-34.5) n.s. 
CD14+/IL-10 6 (0.0-18.5)* 12 (2.7-18.7)** 39 (33-48.5)*
,
** 
p<0.001* 
p<0.001** 
 
 
   Table 4 MFI of transcription factor and cytokines in A- stimulated CD4+ T 
lymphocytes or CD14
+
 cells of patients with AD or MCI and in HC. MFI values 
were calculated on MFI- positive cells. Medians, interquartile ranges and 
statistical values are shown. 
n.s.= not significant. 
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Figure 1 Data observed in a representative MCI patient are shown. A) 
Expression of CD25
high
 T lymphocytes on CD4
+
 cells. B) Expression of 
intracellular FOXP3; cells gated on CD4
+
. C) Intracellular co-expression of PD-1 
(PD-1
neg
 cells) and FOXP3, gated on CD4
+
CD25
high
, representing naïve Treg 
subpopulation. D) Co-expression of surface PD-1 (PD-1
+
 cells) and intracellular 
FOXP3, gated on CD4
+
CD25
high
, representing activated Treg cells. E) Surface 
expression of PD-1 (PD-1
+
 cells), gated on CD4
+
CD25
high
 cells. F) Intracellular 
expression of PD-1 (PD-1
neg
 cells), gated on CD4
+
CD25
high 
cells. In panels E-F 
the percentage of positive cells is indicated above the bar.  
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Figure 2 Regulatory T cells (CD4
+
CD25
high
FOXP3
+
)(A), PD-1
+
 Treg lymphocytes 
(CD4
+
CD25
high
FOXP3
+
PD-1
+
)(B) and PD-1
neg
 Treg lymphocytes 
(CD4
+
CD25
high
FOXP3
+
PD-1
neg
)(C) in peripheral blood of patients affected by 
Alzheimer’s Disease (AD), Mild Cognitive Impairment (MCI) and in healthy controls 
(HC). The boxes stretch from the 25
th
 to the 75
th
 percentile; the lines across the 
boxes indicate the median values; the lines stretching from the boxes indicate 
extreme values. Statistical significance is shown. 
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Figure 3 Summary results of Stimulation Index (S.I.) of CD4
+ 
(A) and CD8
+
 (B) T 
lymphocytes stimulated with A peptide pool in patients affected by AD or MCI 
and in HC.The boxes stretch from the 25
th
 to the 75
th
 percentile; the lines across 
the boxes indicate the median values; the lines stretching from the boxes indicate 
extreme values. Statistical significance is shown. 
 
 
 
Figure 4 Summary results suppressive capacity of Treg cells stimulated with A 
(A) and anti-CD3 and anti-CD28 (B) in patients affected by AD or MCI and in HC. 
In all the experiments a 1:1 Treg: Tresponder ratio was used. The boxes stretch 
from the 25
th
 to the 75
th
 percentile; the lines across the boxes indicate the 
median values; the lines stretching from the boxes indicate extreme values. 
Statistical significance is shown. 
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Figure 5 Summary results of PD-1-expressing CD4
+ 
T lymphocytes (A) and 
representative dotplots of PD-1- expressing CD4
+
 T lymphocytes in A- 
stimulated PBMCs of AD, MCI and HC are shown. In panel A the boxes stretch 
from the 25
th
 to the 75
th
 percentile; the lines across the boxes indicate the 
median values; the lines stretching from the boxes indicate extreme values. 
Statistical significance is shown. In the upper right corner of dotplots (B) the 
percentage of CD4
+
PD-1
+
 is presented. 
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Figure 6 Representative results of PD-L1 expressing A- stimulated CD14
+
 cells 
in AD, MCI and HC. 
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Figure 7 Summary results of IL-10-producing CD14
+
 cells (A) and representative 
dotplots of IL-10- producing CD14
+
 cells in A- stimulated PBMCs of AD, MCI 
and HC are shown. In panel A the boxes stretch from the 25
th
 to the 75
th
 
percentile; the lines across the boxes indicate the median values; the lines 
stretching from the boxes indicate extreme values. Statistical significance is 
shown. In the upper right corner of dotplots (B) the percentage of CD14
+
IL-10
+
 is 
presented. 
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Figure 8 Summary results of IL-10-producing and PD-L1- expressing CD14
+
 
cells (A) and representative dotplots of IL-10- producing and PD-L1- expressing 
CD14
+
 cells in A- stimulated PBMCs of AD, MCI and HC are shown. In panel A 
the boxes stretch from the 25
th
 to the 75
th
 percentile; the lines across the boxes 
indicate the median values; the lines stretching from the boxes indicate extreme 
values. Statistical significance is shown. In the upper right corner of dotplots (B) 
the percentage of CD14
+
PD-L1
+
IL-10
+
 is presented. 
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Figure 9 Summary results of Annexin V- expressing (A) and Annexin V and PD-
1 coexpressing (B) CD4
+
 T lymphocytes in A stimulated PBMCs of AD, MCI 
and HC are presented. Representative dotplots of Annexin V and PD-1 
coexpressing CD4
+
 T lymphocytes in A- stimulated PBMCs of AD, MCI and HC 
are shown. In panel A and B the boxes stretch from the 25
th
 to the 75
th
 
percentile; the lines across the boxes indicate the median values; the lines 
stretching from the boxes indicate extreme values. Statistical significance is 
shown. In the upper right corner of dotplots (C) the percentage of CD4
+
AV
+
PD-1
+
 
is presented. 
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Figure 10 Summary results of Ki67- expressing (A) and representative dotplots 
of Ki67- expressing (B) CD4
+
 T lymphocytes in A stimulated PBMCs of AD, MCI 
and HC are presented. In panel A the boxes stretch from the 25
th
 to the 75
th
 
percentile; the lines across the boxes indicate the median values; the lines 
stretching from the boxes indicate extreme values. Statistical significance is 
shown. In the upper right corner of dotplots (B) the percentage of CD4
+
Ki67
+
 is 
presented. 
Figure 11 Blockade of the PD-1-PD-L1 pathway. Median percentage of A-
stimulated apoptotic CD4
+ 
T cells coexpressing PD-1 and AV, after blockade with 
anti-PD-L1 specific antibody and after isotype matched control antibody (IgG) in 
AD, MCI and HC. 
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Figure 12 Summary results (A) and representative dotplots (B) of IL-9-, IL-21-, 
IL-22- expressing A-stimulated CD4+ T lymphocytes of AD, MCI and HC. In 
panel A the boxes stretch from the 25
th
 to the 75
th
 percentile; the lines across the 
boxes indicate the median values; the lines stretching from the boxes indicate 
extreme values. Statistical significance is shown. In the upper right corner of 
dotplots (B) the percentage of CD4
+
IL-9
+
, CD4
+
IL-21
+
, CD4
+
IL-22
+
 is presented. 
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Figure 13 Summary results (A) and representative dotplots (B) of IL-23-, IL-6-, 
IL-10- producing A-stimulated CD14
+
 cells of AD, MCI and HC. In panel A the 
boxes stretch from the 25
th
 to the 75
th
 percentile; the lines across the boxes 
indicate the median values; the lines stretching from the boxes indicate extreme 
values. Statistical significance is shown. In the upper right corner of dotplots (B) 
the percentage of CD14
+
IL-23
+
, CD14
+
IL-6
+
, CD14
+
IL-10
+
 is presented. 
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Figure 14 Summary results (A) and representative dotplots (B) of RORc/-, 
NFATc- and GATA-3- expressing A-stimulated CD4
+
 T lymphocytes of AD, MCI 
and HC. In panel A the boxes stretch from the 25
th
 to the 75
th
 percentile; the lines 
across the boxes indicate the median values; the lines stretching from the boxes 
indicate extreme values. Statistical significance is shown. In the upper right 
corner of dotplots (B) the percentage of CD4
+
RORc/, CD4
+
NFATc
+
, 
CD4
+
GATA-3
+
 is presented. 
